{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "from dotenv import load_dotenv\n",
    "\n",
    "load_dotenv()\n",
    "MODEL = \"llama2\""
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Scrape the website and split the content ###"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "c:\\Users\\dunca\\OneDrive\\Desktop\\Disertation\\LLM\\venv\\lib\\site-packages\\tqdm\\auto.py:21: TqdmWarning: IProgress not found. Please update jupyter and ipywidgets. See https://ipywidgets.readthedocs.io/en/stable/user_install.html\n",
      "  from .autonotebook import tqdm as notebook_tqdm\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "[Document(metadata={'source': 'C:\\\\Users\\\\dunca\\\\AppData\\\\Local\\\\Temp\\\\tmpc7jzikac.pdf'}, page_content='NITISINONE- nitisinone capsule Analog Pharma\\n\\n----------\\n\\nHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use NITISINONE CAPSULES safely and effectively. See full prescribing information for NITISINONE CAPSULES.\\n\\nNITISINONE capsules, for oral use Initial U.S. Approval: 2002\\n\\nINDICATIONS AND USAGE\\n\\nNitisinone capsules are a hydroxy-phenylpyruvate dioxygenase inhibitor indicated for the treatment of adult and pediatric patients with hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine. (1)\\n\\nDOSAGE AND ADMINISTRATION\\n\\nRecommended Dosage (2.1):'),\n",
       " Document(metadata={'source': 'C:\\\\Users\\\\dunca\\\\AppData\\\\Local\\\\Temp\\\\tmpc7jzikac.pdf'}, page_content='The recommended starting dosage is 0.5 mg/kg orally twice daily. In patients 5 years of age and older who have undetectable serum and urine succinylacetone concentrations after a minimum of 4 weeks on a stable dosage of nitisinone, the total daily dose may be given once daily. Titrate the dosage based on biochemical and/or clinical response, as described in the full prescribing information. The maximum total daily dosage is 2 mg/kg orally.\\n\\nAdministration (2.2):\\n\\nMaintain dietary restriction of tyrosine and phenylalanine Take nitisinone capsules at least one hour before, or two hours after a meal For patients who have difficulties swallowing capsules, the capsules may be opened and the contents suspended in a small amount of water, formula or apple sauce immediately before use.\\n\\nDOSAGE FORMS AND STRENGTHS\\n\\nCapsules: 2 mg, 5 mg, 10 mg, 20 mg. (3)\\n\\nCONTRAINDICATIONS\\n\\nNone (4)\\n\\nWARNINGS AND PRECAUTIONS'),\n",
       " Document(metadata={'source': 'C:\\\\Users\\\\dunca\\\\AppData\\\\Local\\\\Temp\\\\tmpc7jzikac.pdf'}, page_content='Elevated Plasma Tyrosine Levels, Ocular Symptoms, Developmental Delay and Hyperkeratotic Plaques: Inadequate restriction of tyrosine and phenylalanine intake can lead to elevations in plasma tyrosine, which at levels above 500 micromol/L can result in symptoms, intellectual disability and developmental delay or painful hyperkeratotic plaques on the soles and palms; do not adjust nitisinone capsules dosage in order to lower the plasma tyrosine concentration. Obtain slit-lamp examination prior to treatment, regularly during treatment; Reexamine patients if symptoms develop or tyrosine levels are > 500 micromol/L. Assess plasma tyrosine levels in patients with an abrupt change in neurologic status. (5.1) Leukopenia and Severe Thrombocytopenia: Monitor platelet and white blood cell counts. (5.2)\\n\\nADVERSE REACTIONS'),\n",
       " Document(metadata={'source': 'C:\\\\Users\\\\dunca\\\\AppData\\\\Local\\\\Temp\\\\tmpc7jzikac.pdf'}, page_content='ADVERSE REACTIONS\\n\\nMost common adverse reactions (>1%) are elevated tyrosine levels, thrombocytopenia, leukopenia, conjunctivitis, corneal opacity, keratitis, photophobia, eye pain, blepharitis, cataracts, granulocytopenia, epistaxis, pruritus, exfoliative dermatitis, dry skin, maculopapular rash and alopecia. (6.1)\\n\\nTo report SUSPECTED ADVERSE REACTIONS, contact Analog Pharma Inc. at 1-844-884-5505 or medicalinfo@analogpharma.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. DRUG INTERACTIONS CYP2C9 Substrates: Increased systemic exposure of these co-administered drugs; reduce the dosage. Additional dosage adjustments may be needed to maintain therapeutic drug concentrations for narrow therapeutic index drugs. (7) OAT1/OAT3 Substrates: Increased systemic exposure of these co-administered drugs; monitor for potential adverse reactions. (7)\\n\\nSee 17 for PATIENT COUNSELING INFORMATION.\\n\\nRevised: 6/2023'),\n",
       " Document(metadata={'source': 'C:\\\\Users\\\\dunca\\\\AppData\\\\Local\\\\Temp\\\\tmpc7jzikac.pdf'}, page_content='Revised: 6/2023\\n\\nFULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION\\n\\n2.1 Dosage 2.2 Administration\\n\\n3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS\\n\\n5.1 Elevated Plasma Tyrosine Levels, Ocular Symptoms, Developmental Delay and Hyperkeratotic Plaques 5.2 Leukopenia and Severe Thrombocytopenia\\n\\n6 ADVERSE REACTIONS\\n\\n6.1 Clinical Trials Experience\\n\\n7 DRUG INTERACTIONS 8 USE IN SPECIFIC POPULATIONS\\n\\n8.1 Pregnancy 8.2 Lactation 8.4 Pediatric Use 8.5 Geriatric Use 10 OVERDOSAGE 11 DESCRIPTION 12 CLINICAL PHARMACOLOGY\\n\\n12.1 Mechanism of Action 12.2 Pharmacodynamics 12.3 Pharmacokinetics\\n\\n13 NONCLINICAL TOXICOLOGY\\n\\n13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility\\n\\n14 CLINICAL STUDIES 16 HOW SUPPLIED/STORAGE AND HANDLING 17 PATIENT COUNSELING INFORMATION *\\n\\nSections or subsections omitted from the full prescribing information are not listed.\\n\\nFULL PRESCRIBING INFORMATION\\n\\n1 INDICATIONS AND USAGE'),\n",
       " Document(metadata={'source': 'C:\\\\Users\\\\dunca\\\\AppData\\\\Local\\\\Temp\\\\tmpc7jzikac.pdf'}, page_content='Nitisinone capsules are indicated for the treatment of adult and pediatric patients with hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine.\\n\\n2 DOSAGE AND ADMINISTRATION\\n\\n2.1 Dosage\\n\\nStarting Dosage\\n\\nThe recommended starting dosage of nitisinone capsules is 0.5 mg/kg administered orally twice daily.\\n\\nMaintenance Regimen\\n\\nIn patients 5 years of age and older who have undetectable serum and urine succinylacetone concentrations after a minimum of 4 weeks on a stable dosage of nitisinone, the total daily dose of nitisinone capsules may be given once daily (e.g., 1 to 2 mg/kg once daily) [see Clinical Pharmacology (12.2)].\\n\\nDosage Titration\\n\\nTitrate the dosage in each individual patient based on biochemical and/or clinical response.'),\n",
       " Document(metadata={'source': 'C:\\\\Users\\\\dunca\\\\AppData\\\\Local\\\\Temp\\\\tmpc7jzikac.pdf'}, page_content='Monitor plasma and/or urine succinylacetone concentrations, liver function parameters and alpha-fetoprotein levels. If succinylacetone is still detectable in blood or urine 4 weeks after the start of nitisinone treatment, increase the nitisinone dosage to 0.75 mg/kg twice daily. A maximum total daily dosage of 2 mg/kg may be needed based on the evaluation of all biochemical parameters. If the biochemical response is satisfactory (undetectable blood and/or urine succinylacetone), the dosage should be adjusted only according to body weight gain and not according to plasma tyrosine levels. During initiation of therapy, when switching from twice daily to once daily dosing, or if there is a deterioration in the patient’s condition, it may be necessary to follow all available biochemical parameters more closely (i.e. plasma and/or urine succinylacetone, urine 5-aminolevulinate (ALA) and erythrocyte porphobilinogen (PBG)-synthase activity). Maintain plasma tyrosine levels below 500'),\n",
       " Document(metadata={'source': 'C:\\\\Users\\\\dunca\\\\AppData\\\\Local\\\\Temp\\\\tmpc7jzikac.pdf'}, page_content='levels below 500 micromol/L by dietary restriction of tyrosine and phenylalanine intake [see Warnings and Precautions (5.1)]. In patients who develop plasma tyrosine levels above 500 micromol/L, assess dietary tyrosine and phenylalanine intake. Do not adjust the nitisinone capsules dosage in order to lower the plasma tyrosine concentration.'),\n",
       " Document(metadata={'source': 'C:\\\\Users\\\\dunca\\\\AppData\\\\Local\\\\Temp\\\\tmpc7jzikac.pdf'}, page_content='2.2 Administration\\n\\nAdministration of Nitisinone Capsules\\n\\nMaintain dietary restriction of tyrosine and phenylalanine when taking nitisinone capsules. Take at least one hour before, or two hours after a meal [see Clinical Pharmacology (12.3)]. For patients who have difficulty swallowing the capsules, the capsules may be opened and the contents suspended in a small amount of water, formula or apple sauce immediately before use.\\n\\n3 DOSAGE FORMS AND STRENGTHS\\n\\nCapsules: 2 mg, 5 mg, 10 mg and 20 mg white capsules imprinted with the following logo:\\n\\n, followed by “2”, “5”, “10” or “20”, indicating the actual amount of nitisinone in each capsule.\\n\\n4 CONTRAINDICATIONS\\n\\nNone.\\n\\n5 WARNINGS AND PRECAUTIONS\\n\\n5.1 Elevated Plasma Tyrosine Levels, Ocular Symptoms, Developmental Delay and Hyperkeratotic Plaques'),\n",
       " Document(metadata={'source': 'C:\\\\Users\\\\dunca\\\\AppData\\\\Local\\\\Temp\\\\tmpc7jzikac.pdf'}, page_content='Nitisinone is an inhibitor of 4-hydroxyphenyl-pyruvate dioxygenase, an enzyme in the tyrosine metabolic pathway [see Clinical Pharmacology (12.1)]. Therefore, treatment with nitisinone capsules may cause an increase in plasma tyrosine levels in patients with HT-1. Maintain concomitant reduction in dietary tyrosine and phenylalanine while on nitisinone capsules treatment. Do not adjust nitisinone capsules dosage in order to lower the plasma tyrosine concentration. Maintain plasma tyrosine levels below 500 micromol/L. Inadequate restriction of tyrosine and phenylalanine intake can lead to elevations in plasma tyrosine levels and levels greater than 500 micromol/L may lead to the following: Ocular signs and symptoms including corneal ulcers, corneal opacities, keratitis, conjunctivitis, eye pain, and photophobia have been reported in patients treated with nitisinone capsules [see Adverse Reactions (6.1)]. In a clinical study in a non HT-1 population without dietary restriction and'),\n",
       " Document(metadata={'source': 'C:\\\\Users\\\\dunca\\\\AppData\\\\Local\\\\Temp\\\\tmpc7jzikac.pdf'}, page_content='restriction and reported tyrosine levels >500 micromol/L both symptomatic and asymptomatic keratopathies have been observed. Therefore, perform a baseline ophthalmologic examination including slit-lamp examination prior to initiating nitisinone capsules treatment and regularly thereafter. Patients who develop photophobia, eye pain, or signs of inflammation such as redness, swelling, or burning of the eyes or tyrosine levels are > 500 micromol/L during treatment with nitisinone capsules should undergo slit-lamp reexamination and immediate measurement of the plasma tyrosine concentration. Variable degrees of intellectual disability and developmental delay. In patients treated with nitisinone capsules who exhibit an abrupt change in neurologic status, perform a clinical laboratory assessment including plasma tyrosine levels. Painful hyperkeratotic plaques on the soles and palms.'),\n",
       " Document(metadata={'source': 'C:\\\\Users\\\\dunca\\\\AppData\\\\Local\\\\Temp\\\\tmpc7jzikac.pdf'}, page_content='In patients with HT-1 treated with dietary restrictions and nitisinone capsules who develop elevated plasma tyrosine levels, assess dietary tyrosine and phenylalanine intake.\\n\\n5.2 Leukopenia and Severe Thrombocytopenia\\n\\nIn clinical trials, patients treated with nitisinone and dietary restriction developed transient leukopenia (3%), thrombocytopenia (3%), or both (1.5%) [see Adverse Reactions (6.1)]. No patients developed infections or bleeding as a result of the episodes of leukopenia and thrombocytopenia. Monitor platelet and white blood cell counts during nitisinone capsules therapy.\\n\\n6 ADVERSE REACTIONS\\n\\n6.1 Clinical Trials Experience\\n\\nBecause clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.'),\n",
       " Document(metadata={'source': 'C:\\\\Users\\\\dunca\\\\AppData\\\\Local\\\\Temp\\\\tmpc7jzikac.pdf'}, page_content='Nitisinone was studied in one open-label, uncontrolled study of 207 patients with HT-1, ages 0 to 22 years at enrollment (median age 9 months), who were diagnosed with HT-1 by the presence of succinylacetone in the urine or plasma. The starting dose of nitisinone was 0.3 to 0.5 mg/kg twice daily, and the dose was increased in some patients to 1 mg/kg twice daily based on weight, biochemical, and enzyme markers. The recommended starting dosage of nitisinone is 0.5 mg/kg twice daily [see Dosage and Administration (2.1)]. Median duration of treatment was 22 months (range 0.1 to 80 months).'),\n",
       " Document(metadata={'source': 'C:\\\\Users\\\\dunca\\\\AppData\\\\Local\\\\Temp\\\\tmpc7jzikac.pdf'}, page_content='The most serious adverse reactions reported during nitisinone treatment were thrombocytopenia, leukopenia, porphyria, and ocular/visual complaints associated with elevated tyrosine levels [see Warnings and Precautions (5.1, 5.2)]. Fourteen patients experienced ocular/visual events. The duration of the symptoms varied from 5 days to 2 years. Six patients had thrombocytopenia, three of which had platelet counts 30,000/microL or lower. In 4 patients with thrombocytopenia, platelet counts gradually returned to normal (duration up to 47 days) without change in nitisinone dose. No patients developed infections or bleeding as a result of the episodes of leukopenia and thrombocytopenia.'),\n",
       " Document(metadata={'source': 'C:\\\\Users\\\\dunca\\\\AppData\\\\Local\\\\Temp\\\\tmpc7jzikac.pdf'}, page_content='Patients with HT-1 are at increased risk of developing porphyric crises, hepatic neoplasms, and liver failure requiring liver transplantation. These complications of HT-1 were observed in patients treated with nitisinone for a median of 22 months during the clinical trial (liver transplantation 13%, liver failure 7%, malignant hepatic neoplasms 5%, benign hepatic neoplasms 3%, porphyria 1%).\\n\\nThe most common adverse reactions reported in the clinical trial are summarized in Table 1.\\n\\nTABLE 1 Most Common Adverse Reactions in Patients with HT-1 Treated with Nitisinone*\\n\\nElevated tyrosine levels Leukopenia Thrombocytopenia Conjunctivitis Corneal opacity\\n\\n>10% 3% 3% 2% 2%\\n\\nKeratitis Photophobia Eye pain Blepharitis Cataracts Granulocytopenia Epistaxis Pruritus Exfoliative dermatitis Dry skin Maculopapular rash Alopecia\\n\\n2% 2% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1%\\n\\nreported in at least 1% of patients'),\n",
       " Document(metadata={'source': 'C:\\\\Users\\\\dunca\\\\AppData\\\\Local\\\\Temp\\\\tmpc7jzikac.pdf'}, page_content='Adverse reactions reported in less than 1% of the patients, included death, seizure, brain tumor, encephalopathy, hyperkinesia, cyanosis, abdominal pain, diarrhea, enanthema, gastrointestinal hemorrhage, melena, elevated hepatic enzymes, liver enlargement, hypoglycemia, septicemia, and bronchitis.\\n\\n7 DRUG INTERACTIONS\\n\\nNitisinone is a moderate CYP2C9 inhibitor, a weak CYP2E1 inducer and an inhibitor of OAT1/OAT3. Table 2 includes drugs with clinically important drug interactions when administered concomitantly with nitisinone capsules and instructions for preventing or managing them.\\n\\nTABLE 2: Clinically Relevant Interactions Affecting Co-Administered Drugs\\n\\nSensitive CYP2C9 Substrates (e.g., celecoxib, tolbutamide) or CYP2C9 Substrates with a Narrow Therapeutic Index (e.g. phenytoin, warfarin)\\n\\nClinical Impact\\n\\nIntervention'),\n",
       " Document(metadata={'source': 'C:\\\\Users\\\\dunca\\\\AppData\\\\Local\\\\Temp\\\\tmpc7jzikac.pdf'}, page_content='Intervention\\n\\nIncreased exposure of the co-administered drugs metabolized by CYP2C9. [see Clinical Pharmacology (12.3)] Reduce the dosage of the co-administered drugs metabolized by CYP2C9 drug by half. Additional dosage adjustment may be needed to maintain therapeutic drug concentrations for narrow therapeutic index drugs. See prescribing information for those drugs.\\n\\nOAT1/OAT3 Substrates (e.g., adefovir, ganciclovir, methotrexate)\\n\\nClinical Impact\\n\\nIntervention\\n\\nIncreased exposure of the interacting drug [See Clinical Pharmacology (12.3)] Monitor for potential adverse reactions related to the co-administered drug.\\n\\n8 USE IN SPECIFIC POPULATIONS\\n\\n8.1 Pregnancy\\n\\nRisk Summary'),\n",
       " Document(metadata={'source': 'C:\\\\Users\\\\dunca\\\\AppData\\\\Local\\\\Temp\\\\tmpc7jzikac.pdf'}, page_content='Risk Summary\\n\\nLimited available data with nitisinone use in pregnant women are not sufficient to determine a drug-associated risk of adverse developmental outcomes. Animal reproduction studies have been conducted for nitisinone. In these studies, nitisinone was administered to mice and rabbits during organogenesis with oral doses of nitisinone up to 20 and 8 times respectively, the recommended initial dose of 1 mg/kg/day. In mice, nitisinone caused incomplete skeletal ossification of fetal bones and decreased pup survival at doses 0.4 times the recommended initial dose, and increased gestational length at doses 4 times the recommended initial dose. In rabbits, nitisinone caused maternal toxicity and incomplete skeletal ossification of fetal bones at doses 1.6 times the recommended initial dose [see Data].'),\n",
       " Document(metadata={'source': 'C:\\\\Users\\\\dunca\\\\AppData\\\\Local\\\\Temp\\\\tmpc7jzikac.pdf'}, page_content='The background risk of major birth defects and miscarriage for the indicated population are unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.\\n\\nData\\n\\nAnimal Data'),\n",
       " Document(metadata={'source': 'C:\\\\Users\\\\dunca\\\\AppData\\\\Local\\\\Temp\\\\tmpc7jzikac.pdf'}, page_content='Data\\n\\nAnimal Data\\n\\nReproduction studies have been performed in mice at oral doses of about 0.4, 4 and 20 times the recommended initial dose (1 mg/kg/day) and in rabbits at oral doses of about 1.6, 4 and 8 times the recommended initial dose based on the body surface area. In mice, nitisinone has been shown to cause incomplete skeletal ossification of fetal bones at 0.4, 4 and 20 times the recommended initial dose, increased gestational length at 4 and 20 times the recommended initial dose, and decreased pup survival at 0.4 times the recommended initial dose based on the body surface area. In rabbits, nitisinone caused incomplete skeletal ossification of fetal bones at 1.6, 4 and 8 times the recommended initial dose based on the body surface area.\\n\\n8.2 Lactation\\n\\nRisk Summary'),\n",
       " Document(metadata={'source': 'C:\\\\Users\\\\dunca\\\\AppData\\\\Local\\\\Temp\\\\tmpc7jzikac.pdf'}, page_content='Risk Summary\\n\\nThere are no data on the presence of nitisinone in human milk, the effects on the breastfed infant, or the effects on milk production. Data suggest that nitisinone is present in rat milk due to findings of ocular toxicity and lower body weight seen in drug naive nursing rat pups. The development and health benefits of breastfeeding should be considered along with the mother’s clinical need for nitisinone capsules and any potential adverse effects on the breastfed infant from nitisinone capsules or from the underlying maternal condition.\\n\\n8.4 Pediatric Use\\n\\nThe safety and effectiveness of nitisinone have been established in pediatric patients for the treatment of HT-1 in combination with dietary restriction of tyrosine and phenylalanine. Use of nitisinone in pediatric patients is supported by evidence from one open-label, uncontrolled clinical study conducted in 207 patients with HT-1 ages 0 to 22\\n\\nyears (median age 9 months) [see Clinical Studies (14)].'),\n",
       " Document(metadata={'source': 'C:\\\\Users\\\\dunca\\\\AppData\\\\Local\\\\Temp\\\\tmpc7jzikac.pdf'}, page_content='8.5 Geriatric Use\\n\\nClinical studies of nitisinone did not include any subjects aged 65 and over. No pharmacokinetic studies of nitisinone have been performed in geriatric patients. In general, dose selection for an elderly patient should be cautious reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and concomitant disease or other drug therapy in this patient population.\\n\\n10 OVERDOSAGE'),\n",
       " Document(metadata={'source': 'C:\\\\Users\\\\dunca\\\\AppData\\\\Local\\\\Temp\\\\tmpc7jzikac.pdf'}, page_content='10 OVERDOSAGE\\n\\nAccidental ingestion of nitisinone capsules by individuals eating normal diets not restricted in tyrosine and phenylalanine will result in elevated tyrosine levels. In healthy subjects given a single 1 mg/kg dose of nitisinone, the plasma tyrosine level reached a maximum of 1200 micromol/L at 48 to 120 hours after dosing. After a washout period of 14 days, the mean value of plasma tyrosine was still 808 micromol/L. Fasted follow-up samples obtained from volunteers several weeks later showed tyrosine values back to normal. There were no reports of changes in vital signs or laboratory data of any clinical significance. One patient reported sensitivity to sunlight. Hypertyrosinemia has been reported with nitisinone treatment [see Warnings and Precautions (5.1)].\\n\\n11 DESCRIPTION'),\n",
       " Document(metadata={'source': 'C:\\\\Users\\\\dunca\\\\AppData\\\\Local\\\\Temp\\\\tmpc7jzikac.pdf'}, page_content='11 DESCRIPTION\\n\\nNitisinone capsules contain nitisinone, which is a hydroxyphenyl-pyruvate dioxygenase inhibitor indicated as an adjunct to dietary restriction of tyrosine and phenylalanine in the treatment of hereditary tyrosinemia type 1 (HT-1).\\n\\nNitisinone occurs as white to yellowish-white, crystalline powder. It is practically insoluble in water, soluble in 2M sodium hydroxide and in methanol, and sparingly soluble in alcohol.\\n\\nChemically, nitisinone is 2-(2-nitro-4-trifluoromethylbenzoyl) cyclohexane-1,3-dione, and the structural formula is:\\n\\nFigure 1. The molecular formula is C H F NO with a relative mass of 329.23\\n\\n14 10 3\\n\\n5\\n\\nHard, white-opaque capsule, marked as “2”, “5”, “10” or “20” on the capsule body indicating the strengths of nitisinone, intended for oral administration, and the following'),\n",
       " Document(metadata={'source': 'C:\\\\Users\\\\dunca\\\\AppData\\\\Local\\\\Temp\\\\tmpc7jzikac.pdf'}, page_content='logo on the capsule cap: nitisinone, plus pre-gelatinized starch and stearic acid. The capsule shell is gelatin and titanium dioxide and the blue imprint is composed of FD & C Blue #2-Aluminum Lake, shellac, propylene glycol and strong ammonia solution.\\n\\n. Each capsule contains 2 mg, 5 mg, 10 mg or 20 mg\\n\\n12 CLINICAL PHARMACOLOGY\\n\\n12.1 Mechanism of Action'),\n",
       " Document(metadata={'source': 'C:\\\\Users\\\\dunca\\\\AppData\\\\Local\\\\Temp\\\\tmpc7jzikac.pdf'}, page_content='Nitisinone is a competitive inhibitor of 4-hydroxyphenyl-pyruvate dioxygenase, an enzyme upstream of fumarylacetoacetate hydrolase (FAH) in the tyrosine catabolic pathway. By inhibiting the normal catabolism of tyrosine in patients with HT-1, nitisinone prevents the accumulation of the catabolic intermediates maleylacetoacetate and fumarylacetoacetate. In patients with HT-1, these catabolic intermediates are converted to the toxic metabolites succinylacetone and succinylacetoacetate, which are responsible for the observed liver and kidney toxicity. Succinylacetone can also inhibit the porphyrin synthesis pathway leading to the accumulation of 5-aminolevulinate, a neurotoxin responsible for the porphyric crises characteristic of HT-1.\\n\\n12.2 Pharmacodynamics'),\n",
       " Document(metadata={'source': 'C:\\\\Users\\\\dunca\\\\AppData\\\\Local\\\\Temp\\\\tmpc7jzikac.pdf'}, page_content='In a clinical study, patients with HT-1 were diagnosed by the presence of succinylacetone in urine or plasma and treated with nitisinone [see Clinical Studies (14)]. In all 186 patients whose urine succinylacetone was measured, the urinary succinylacetone concentration decreased to less than 1 mmol/mol creatinine, the lower limit of quantitation. The median time to normalization of urine succinylacetone was 0.3 months. The probability of recurrence of abnormal values of urine succinylacetone was 1% at a nitisinone concentration of 37 micromol/L (95% confidence interval: 23, 51 micromol/L). In 87% (150/172) of patients whose plasma succinylacetone was measured, the plasma succinylacetone concentration decreased to less than 0.1 micromol/L, the lower limit of quantitation. The median time to normalization of plasma succinylacetone was 3.9 months.'),\n",
       " Document(metadata={'source': 'C:\\\\Users\\\\dunca\\\\AppData\\\\Local\\\\Temp\\\\tmpc7jzikac.pdf'}, page_content='In another study, comparing two dosing regimens, succinylacetone was measured in urine and/or blood in 16 patients with HT-1 aged 5 years to 24 years. All study patients were on a stable nitisinone daily dosage (0.4 mg/kg/day to 1 mg/kg/day) during both study dosing regimens. After at least 4 weeks of twice daily dosing with nitisinone, both the urine and/or blood succinylacetone concentrations were below the limit of quantitation for the assay. Patients were then switched to once daily dosing with the same total daily dosage of nitisinone and blood and/or urine succinylacetone concentrations remained undetectable when measured following at least 4 weeks of treatment with once daily dosing.'),\n",
       " Document(metadata={'source': 'C:\\\\Users\\\\dunca\\\\AppData\\\\Local\\\\Temp\\\\tmpc7jzikac.pdf'}, page_content='Nitisinone inhibits catabolism of the amino acid tyrosine and can result in elevated plasma levels of tyrosine. Therefore, treatment with nitisinone requires restriction of the dietary intake of tyrosine and phenylalanine to prevent the toxicity associated with elevated plasma levels of tyrosine [see Warnings and Precautions (5.1)].\\n\\n12.3 Pharmacokinetics\\n\\nThe single-dose pharmacokinetics of nitisinone have been studied in healthy adult subjects and the multiple-dose pharmacokinetics have been studied for nitisinone capsules in healthy subjects.\\n\\nAbsorption\\n\\nThe pharmacokinetic characteristics following single oral administration of nitisinone 30 mg under fasting conditions are shown in Table 3. The multiple-dose characteristics of nitisinone 80 mg once daily are shown in Table 4. Steady-state (SS) was reached within 14 days dosing in all subjects.\\n\\nTABLE 3'),\n",
       " Document(metadata={'source': 'C:\\\\Users\\\\dunca\\\\AppData\\\\Local\\\\Temp\\\\tmpc7jzikac.pdf'}, page_content='TABLE 3\\n\\nNitisinone Arithmetic Mean (CV%) Pharmacokinetic Parameters in Healthy Subjects Following a Single Oral 30 mg Dose of Nitisinone Under Fasting Conditions\\n\\nTreatment\\n\\nNitisinone capsules (n=12)\\n\\nC (micromol/L) [range]\\n\\nmax\\n\\n10.5 (26)\\n\\nt max (h) [range] 3.5 [0.8 to 8.0]\\n\\n\\n\\nAUC (micromol·h/L) [range]\\n\\n0-72h\\n\\n406 (13)\\n\\npresented as median [range]\\n\\nTABLE 4\\n\\nNitisinone Arithmetic Mean (CV%) Pharmacokinetic Parameters in Healthy Subjects Following Repeated Once Daily Administration of 80 mg Nitisinone Under Fasting Conditions\\n\\nTreatment\\n\\nNitisinone capsules (n=18)\\n\\nC (micromol/L) (CV%)\\n\\nmax,ss\\n\\n120 (23)\\n\\nC (micromol/L) [range]\\n\\nmin,ss\\n\\n73 (24)\\n\\nt (h) [range] 4.0 [0.0 to 16.0]\\n\\nmax,ss\\n\\n\\n\\nAUC (micromol·h/L) [range]\\n\\n0-24h,ss\\n\\n2204 (18)\\n\\npresented as median [range]\\n\\nFood Effect: No food effect study was conducted with nitisinone capsules [see Dosage and Administration (2.2)].\\n\\nDistribution'),\n",
       " Document(metadata={'source': 'C:\\\\Users\\\\dunca\\\\AppData\\\\Local\\\\Temp\\\\tmpc7jzikac.pdf'}, page_content='Distribution\\n\\nIn vitro binding of nitisinone to human plasma proteins is greater than 95% at 50 micromolar concentration.\\n\\nElimination\\n\\nThe mean terminal plasma half-life of single dose nitisinone in healthy male subjects is 54 hours. The mean (CV%) apparent plasma clearance in 18 healthy adults following multiple once daily doses of nitisinone 80 mg is 113 (16) mL/h.\\n\\nMetabolism: In vitro studies have shown that nitisinone is relatively stable in human liver microsomes with minor metabolism possibly mediated by CYP3A4 enzyme.\\n\\nExcretion: Renal elimination of nitisinone is of minor importance, since the mean of the fraction of dose excreted as unchanged nitisinone in the urine (fe(%)) was 3.0% (n=3) following multiple oral doses of 80 mg daily in healthy subjects. The estimated mean (CV%) renal clearance of nitisinone was 0.003 L/h (25%).\\n\\nDrug Interaction Studies'),\n",
       " Document(metadata={'source': 'C:\\\\Users\\\\dunca\\\\AppData\\\\Local\\\\Temp\\\\tmpc7jzikac.pdf'}, page_content='Nitisinone does not inhibit CYP2D6. Nitisinone is a moderate inhibitor of CYP2C9, and a weak inducer of CYP2E1 (Table 5). Nitisinone is an inhibitor of OAT1/3 (Table 5).\\n\\nTABLE 5.\\n\\nPercent change in AUC Presence of Nitisinone in 18 Healthy Subjects\\n\\nand C\\n\\nfor Co-administered Drugs in the\\n\\n0-∞\\n\\nmax\\n\\nCo- administered a drug\\n\\nDose of Co- administered Drug (Route of Administration)\\n\\nEffect of Nitisinone on the Pharmacokinetics of Co- administered Drug AUC\\n\\nb\\n\\nC\\n\\n0-∞\\n\\nmax\\n\\nCYP2C9 Substrate c Tolbutamide CYP2E1 Substrate Chlorzoxazone OAT1/3 Substrate Furosemide\\n\\n500 mg (oral)\\n\\n250 mg (oral)\\n\\n20 mg (intravenous)\\n\\n131%↑\\n\\n27%↓\\n\\n72%↑\\n\\n16%↑\\n\\n18%↓\\n\\n12%↑\\n\\n↑= increased; ↓= decreased\\n\\na\\n\\nThe interacting drug was administered alone on Day 1 and together with Nitisinone on Day 17.\\n\\nb Multiple doses of 80 mg nitisinone were administered daily alone from Day 3 to Day 16.\\n\\nc 16 subjects in Period 2 received nitisinone and tolbutamide while 18 subjects in Period 1 received nitisinone alone.'),\n",
       " Document(metadata={'source': 'C:\\\\Users\\\\dunca\\\\AppData\\\\Local\\\\Temp\\\\tmpc7jzikac.pdf'}, page_content='In vitro Studies Where Drug Interaction Potential Was Not Evaluated Clinically\\n\\nIn vitro studies showed that nitisinone does not inhibit CYP1A2, 2C19, or 3A4. Nitisinone does not induce CYP1A2, 2B6 or 3A4/5. Nitisinone does not inhibit P-gp, BCRP, OATP1B1, OATP1B3 and OCT2-mediated transports at therapeutically relevant concentrations.\\n\\n13 NONCLINICAL TOXICOLOGY\\n\\n13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility\\n\\nThe carcinogenic potential of nitisinone was assessed in a 26-week oral (gavage) carcinogenicity study in Tg.rasH2 mice. There were no drug-related neoplastic findings in male or female Tg.rasH2 mice at doses up to 100 mg/kg/day nitisinone (approximately 8.1 times the recommended initial dose of 1 mg/kg/day on a body surface area basis).\\n\\nNitisinone was not genotoxic in the Ames test and the in vivo mouse liver unscheduled DNA synthesis (UDS) test. Nitisinone was mutagenic in the mouse lymphoma cell (L5178Y/TK micronucleus test.\\n\\n+/-'),\n",
       " Document(metadata={'source': 'C:\\\\Users\\\\dunca\\\\AppData\\\\Local\\\\Temp\\\\tmpc7jzikac.pdf'}, page_content='+/-\\n\\n) forward mutation test and in an in vivo mouse bone marrow\\n\\nIn a single dose-group study in rats given 100 mg/kg (16.2 times the recommended initial dose of 1 mg/kg/day on a body surface area basis), reduced litter size, decreased pup weight at birth, and decreased survival of pups after birth was demonstrated.\\n\\n14 CLINICAL STUDIES'),\n",
       " Document(metadata={'source': 'C:\\\\Users\\\\dunca\\\\AppData\\\\Local\\\\Temp\\\\tmpc7jzikac.pdf'}, page_content='The efficacy and safety of nitisinone in patients with HT-1 was evaluated in one open- label, uncontrolled study of 207 patients with HT-1, ages 0 to 22 years at enrollment (median age 9 months). Patients were diagnosed with HT-1 by the presence of succinylacetone in the urine or plasma. All patients were treated with nitisinone at a starting dose of 0.3 to 0.5 mg/kg twice daily, and the dose was increased in some patients to 1 mg/kg twice daily based on weight, liver and kidney function tests, platelet count, serum amino acids, urinary phenolic acid, plasma and urine succinylacetone, erythrocyte PBG-synthase, and urine 5-ALA. The median duration of treatment was 22 months (range less than 1 month to 80 months). Efficacy was assessed by comparison of survival and incidence of liver transplant to historical controls.'),\n",
       " Document(metadata={'source': 'C:\\\\Users\\\\dunca\\\\AppData\\\\Local\\\\Temp\\\\tmpc7jzikac.pdf'}, page_content='For patients presenting with HT-1 younger than 2 months of age who were treated with dietary restriction and nitisinone, 2- and 4-year survival probabilities were 88% and 88%, respectively. Data from historical controls showed that patients presenting with HT-1 at younger than 2 months of age and treated with dietary restriction alone had 2- and 4- year survival probabilities of 29% and 29%, respectively. For patients presenting with HT-1 between 2 months and 6 months of age who were treated with dietary restriction and nitisinone, 2- and 4-year survival probabilities were 94% and 94%, respectively. Data for historical controls showed that patients presenting with HT-1 between 2 months and 6 months of age treated with dietary restriction alone had 2- and 4-year survival probabilities of 74% and 60%, respectively.\\n\\nThe effects of nitisinone on urine and plasma succinylacetone, porphyrin metabolism, and urinary alpha-1-microglobulin were also assessed in this clinical study.'),\n",
       " Document(metadata={'source': 'C:\\\\Users\\\\dunca\\\\AppData\\\\Local\\\\Temp\\\\tmpc7jzikac.pdf'}, page_content='Porphyria-like crisis were reported in 3 patients (0.3% of cases per year) during the clinical study. This compares to an incidence of 5 to 20% of cases per year expected as part of the natural history of the disorder. An assessment of porphyria-like crises was performed because these events are commonly reported in patients with HT-1 who are not treated with nitisinone.\\n\\nUrinary alpha-1-microglobulin, a proposed marker of proximal tubular dysfunction, was measured in 100 patients at baseline. The overall median pretreatment level was 4.3 grams/mol creatinine. After one year of treatment in a subgroup of patients (N=100), overall median alpha-1-microglobulin decreased by 1.5 grams/mol creatinine. In patients 24 months of age and younger in whom multiple values were available (N=65), median'),\n",
       " Document(metadata={'source': 'C:\\\\Users\\\\dunca\\\\AppData\\\\Local\\\\Temp\\\\tmpc7jzikac.pdf'}, page_content='alpha-1-microglobulin levels decreased from 5.0 to 3.0 grams/mol creatinine (reference value for age less than or equal to 12 grams/mol creatinine). In patients older than 24 months in whom multiple values were available (N=35), median alpha-1-microglobulin levels decreased from 2.8 to 2.0 grams/mol creatinine (reference for age less than or equal to 6 grams/mol creatinine).\\n\\nThe long-term effect of nitisinone on hepatic function was not assessed.\\n\\n16 HOW SUPPLIED/STORAGE AND HANDLING\\n\\nWhite capsules marked in blue with the following logo on the capsule cap: identified as 2 mg, 5 mg, 10 mg or 20 mg strengths of nitisinone on the capsule body. The capsules are packed in a high-density polyethylene container with a child-resistant polypropylene snap-on cap. Each bottle contains 60 capsules.\\n\\n2 mg white capsules imprinted with the following logo on the capsule cap: on the capsule body in blue ink, NDC 70505-202-60'),\n",
       " Document(metadata={'source': 'C:\\\\Users\\\\dunca\\\\AppData\\\\Local\\\\Temp\\\\tmpc7jzikac.pdf'}, page_content='5 mg white capsules imprinted with the following logo on the capsule cap: on the capsule body in blue ink, NDC 70505-205-60\\n\\n10 mg white capsules imprinted with the following logo on the capsule cap: “10” on the capsule body in blue ink, NDC 70505-210-60\\n\\n20 mg white capsules imprinted with the following logo on the capsule cap: “20” on the capsule body in blue ink, NDC 70505-220-60\\n\\nStore at 25ºC (77ºF); excursions permitted to 15º–30ºC (59º - 86ºF) [see USP Controlled Room Temperature]\\n\\n17 PATIENT COUNSELING INFORMATION\\n\\nAdministration [see Dosage and Administration (2.2)]\\n\\nAdministration of Nitisinone Capsules\\n\\nMaintain dietary restriction of tyrosine and phenylalanine when taking nitisinone capsules. Take at least one hour before, or two hours after a meal. For patients who have difficulty swallowing the capsules, the capsules may be opened and the contents suspended in a small amount of water, formula or apple sauce immediately before use.'),\n",
       " Document(metadata={'source': 'C:\\\\Users\\\\dunca\\\\AppData\\\\Local\\\\Temp\\\\tmpc7jzikac.pdf'}, page_content='Elevated Plasma Tyrosine Levels, Ocular Symptoms, Developmental Delay and Hyperkeratotic Plaques\\n\\nInform patients that inadequate restriction may be associated with ocular signs and\\n\\n, and\\n\\n, and “2”\\n\\n, and “5”\\n\\n, and\\n\\n, and\\n\\nsymptoms, intellectual disability and developmental delay, and painful hyperkeratotic plaques on the soles and palms. Advise patients and caregivers of the need to maintain dietary restriction of tyrosine and phenylalanine and to report any unexplained ocular, neurologic, or other symptoms promptly to their healthcare provider [see Warnings and Precautions (5.1))].\\n\\nDistributed by: Analog Pharma Inc. Princeton, NJ, 08540 www.analogpharma.com\\n\\nRevision date: 06/2023\\n\\nPRINCIPAL DISPLAY PANEL - 2 mg Container\\n\\nNDC 70505-202-60 Nitisinone Capsules 2 mg\\n\\n60 capsules\\n\\nPRINCIPAL DISPLAY PANEL - 2 mg Carton\\n\\nNDC 70505-202-60 Nitisinone Capsules 2 mg\\n\\nFor Oral Use\\n\\nANALOG PHARMA\\n\\n60 capsules\\n\\nPRINCIPAL DISPLAY PANEL - 5 mg Container'),\n",
       " Document(metadata={'source': 'C:\\\\Users\\\\dunca\\\\AppData\\\\Local\\\\Temp\\\\tmpc7jzikac.pdf'}, page_content='NDC 70505-205-60 Nitisinone Capsules 5 mg\\n\\n60 capsules\\n\\nPRINCIPAL DISPLAY PANEL - 5 mg Carton\\n\\nNDC 70505-205-60 Nitisinone Capsules 5 mg\\n\\nFor Oral Use\\n\\nANALOG PHARMA\\n\\n60 capsules\\n\\nPRINCIPAL DISPLAY PANEL - 10 mg Container\\n\\nNDC 70505-210-60 Nitisinone Capsules 10 mg\\n\\n60 capsules\\n\\nPRINCIPAL DISPLAY PANEL - 10 mg Carton\\n\\nNDC 70505-210-60 Nitisinone Capsules 10 mg\\n\\nFor Oral Use\\n\\nANALOG PHARMA\\n\\n60 capsules\\n\\nPRINCIPAL DISPLAY PANEL - 20 mg Container\\n\\nNDC 70505-220-60 Nitisinone Capsules 20 mg\\n\\n60 capsules\\n\\nPRINCIPAL DISPLAY PANEL - 20 mg Carton\\n\\nNDC 70505-220-60 Nitisinone Capsules 20 mg\\n\\nFor Oral Use\\n\\nANALOG PHARMA\\n\\n60 capsules\\n\\nNITISINONE nitisinone capsule\\n\\nProduct Information\\n\\nProduct Type\\n\\nHUMAN PRESCRIPTION DRUG\\n\\nItem Code (Source)\\n\\nRoute of Administration\\n\\nORAL\\n\\nActive Ingredient/Active Moiety\\n\\nIngredient Name\\n\\nBasis of Strength\\n\\nNITISINONE (UNII: K5BN214699) (NITISINONE - UNII:K5BN214699)\\n\\nNITISINONE\\n\\nInactive Ingredients\\n\\nIngredient Name'),\n",
       " Document(metadata={'source': 'C:\\\\Users\\\\dunca\\\\AppData\\\\Local\\\\Temp\\\\tmpc7jzikac.pdf'}, page_content='Ingredient Name\\n\\nMODIFIED CORN STARCH (1-OCTENYL SUCCINIC ANHYDRIDE) (UNII: 461P5CJN6T)\\n\\nGELATIN, UNSPECIFIED (UNII: 2G86QN327L)\\n\\nSTEARIC ACID (UNII: 4ELV7Z65AP)\\n\\nTITANIUM DIOXIDE (UNII: 15FIX9V2JP)\\n\\nFD&C BLUE NO. 2--ALUMINUM LAKE (UNII: 4AQJ3LG584)\\n\\nSHELLAC (UNII: 46N107B71O)\\n\\nPROPYLENE GLYCOL (UNII: 6DC9Q167V3)\\n\\nAMMONIA (UNII: 5138Q19F1X)\\n\\nNDC:70505-202\\n\\nStrength\\n\\n2 mg\\n\\nStrength\\n\\nProduct Characteristics\\n\\nColor\\n\\nwhite\\n\\nScore\\n\\nno score\\n\\nShape\\n\\nCAPSULE\\n\\nSize\\n\\n16mm\\n\\nFlavor\\n\\nImprint Code\\n\\n2;logo\\n\\nContains\\n\\nPackaging\\n\\n# Item Code\\n\\nPackage Description\\n\\nMarketing Start Date\\n\\nMarketing End Date\\n\\n1\\n\\nNDC:70505- 202-60\\n\\n1 in 1 CARTON\\n\\n06/15/2022\\n\\n1\\n\\n60 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product\\n\\nMarketing Information\\n\\nMarketing Category\\n\\nApplication Number or Monograph Citation\\n\\nMarketing Start Date\\n\\nMarketing End Date\\n\\nANDA\\n\\nANDA212390\\n\\n06/15/2022\\n\\nNITISINONE nitisinone capsule\\n\\nProduct Information\\n\\nProduct Type\\n\\nHUMAN PRESCRIPTION DRUG\\n\\nItem Code (Source)\\n\\nNDC:70505-205'),\n",
       " Document(metadata={'source': 'C:\\\\Users\\\\dunca\\\\AppData\\\\Local\\\\Temp\\\\tmpc7jzikac.pdf'}, page_content='NDC:70505-205\\n\\nRoute of Administration\\n\\nORAL\\n\\nActive Ingredient/Active Moiety\\n\\nIngredient Name\\n\\nBasis of Strength\\n\\nStrength\\n\\nNITISINONE (UNII: K5BN214699) (NITISINONE - UNII:K5BN214699)\\n\\nNITISINONE\\n\\n5 mg\\n\\nInactive Ingredients\\n\\nIngredient Name\\n\\nStrength\\n\\nMODIFIED CORN STARCH (1-OCTENYL SUCCINIC ANHYDRIDE) (UNII: 461P5CJN6T)\\n\\nGELATIN, UNSPECIFIED (UNII: 2G86QN327L)\\n\\nSTEARIC ACID (UNII: 4ELV7Z65AP)\\n\\nTITANIUM DIOXIDE (UNII: 15FIX9V2JP)\\n\\nFD&C BLUE NO. 2--ALUMINUM LAKE (UNII: 4AQJ3LG584)\\n\\nSHELLAC (UNII: 46N107B71O)\\n\\nPROPYLENE GLYCOL (UNII: 6DC9Q167V3)\\n\\nAMMONIA (UNII: 5138Q19F1X)\\n\\nProduct Characteristics\\n\\nColor\\n\\nwhite\\n\\nScore\\n\\nno score\\n\\nShape\\n\\nCAPSULE\\n\\nSize\\n\\n16mm\\n\\nFlavor\\n\\nImprint Code\\n\\n5;logo\\n\\nContains\\n\\nPackaging\\n\\n# Item Code\\n\\nPackage Description\\n\\nMarketing Start Date\\n\\nMarketing End Date\\n\\n1\\n\\nNDC:70505- 205-60\\n\\n1 in 1 CARTON\\n\\n06/15/2022\\n\\n1\\n\\n60 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product\\n\\nMarketing Information\\n\\nMarketing Category\\n\\nApplication Number or Monograph Citation'),\n",
       " Document(metadata={'source': 'C:\\\\Users\\\\dunca\\\\AppData\\\\Local\\\\Temp\\\\tmpc7jzikac.pdf'}, page_content='Marketing Start Date\\n\\nMarketing End Date\\n\\nANDA\\n\\nANDA212390\\n\\n06/15/2022\\n\\nNITISINONE nitisinone capsule\\n\\nProduct Information\\n\\nProduct Type\\n\\nHUMAN PRESCRIPTION DRUG\\n\\nItem Code (Source)\\n\\nNDC:70505-210\\n\\nRoute of Administration\\n\\nORAL\\n\\nActive Ingredient/Active Moiety\\n\\nIngredient Name\\n\\nBasis of Strength\\n\\nStrength\\n\\nNITISINONE (UNII: K5BN214699) (NITISINONE - UNII:K5BN214699)\\n\\nNITISINONE\\n\\n10 mg\\n\\nInactive Ingredients\\n\\nIngredient Name\\n\\nStrength\\n\\nMODIFIED CORN STARCH (1-OCTENYL SUCCINIC ANHYDRIDE) (UNII: 461P5CJN6T)\\n\\nGELATIN, UNSPECIFIED (UNII: 2G86QN327L)\\n\\nSTEARIC ACID (UNII: 4ELV7Z65AP)\\n\\nTITANIUM DIOXIDE (UNII: 15FIX9V2JP)\\n\\nFD&C BLUE NO. 2--ALUMINUM LAKE (UNII: 4AQJ3LG584)\\n\\nSHELLAC (UNII: 46N107B71O)\\n\\nPROPYLENE GLYCOL (UNII: 6DC9Q167V3)\\n\\nAMMONIA (UNII: 5138Q19F1X)\\n\\nProduct Characteristics\\n\\nColor\\n\\nwhite\\n\\nScore\\n\\nno score\\n\\nShape\\n\\nCAPSULE\\n\\nSize\\n\\n18mm\\n\\nFlavor\\n\\nImprint Code\\n\\n10;logo\\n\\nContains\\n\\nPackaging\\n\\n# Item Code\\n\\nPackage Description\\n\\nMarketing Start Date\\n\\nMarketing End Date\\n\\n1\\n\\nNDC:70505- 210-60'),\n",
       " Document(metadata={'source': 'C:\\\\Users\\\\dunca\\\\AppData\\\\Local\\\\Temp\\\\tmpc7jzikac.pdf'}, page_content='NDC:70505- 210-60\\n\\n1 in 1 CARTON\\n\\n06/15/2022\\n\\n1\\n\\n60 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product\\n\\nMarketing Information\\n\\nMarketing Category\\n\\nApplication Number or Monograph Citation\\n\\nMarketing Start Date\\n\\nMarketing End Date\\n\\nANDA\\n\\nANDA212390\\n\\n06/15/2022\\n\\nNITISINONE nitisinone capsule\\n\\nProduct Information\\n\\nProduct Type\\n\\nHUMAN PRESCRIPTION DRUG\\n\\nItem Code (Source)\\n\\nNDC:70505-220\\n\\nRoute of Administration\\n\\nORAL\\n\\nActive Ingredient/Active Moiety\\n\\nIngredient Name\\n\\nBasis of Strength\\n\\nStrength\\n\\nNITISINONE (UNII: K5BN214699) (NITISINONE - UNII:K5BN214699)\\n\\nNITISINONE\\n\\n20 mg\\n\\nInactive Ingredients\\n\\nIngredient Name\\n\\nStrength\\n\\nMODIFIED CORN STARCH (1-OCTENYL SUCCINIC ANHYDRIDE) (UNII: 461P5CJN6T)\\n\\nGELATIN, UNSPECIFIED (UNII: 2G86QN327L)\\n\\nSTEARIC ACID (UNII: 4ELV7Z65AP)\\n\\nTITANIUM DIOXIDE (UNII: 15FIX9V2JP)\\n\\nFD&C BLUE NO. 2--ALUMINUM LAKE (UNII: 4AQJ3LG584)\\n\\nSHELLAC (UNII: 46N107B71O)\\n\\nPROPYLENE GLYCOL (UNII: 6DC9Q167V3)\\n\\nAMMONIA (UNII: 5138Q19F1X)\\n\\nProduct Characteristics\\n\\nColor\\n\\nwhite'),\n",
       " Document(metadata={'source': 'C:\\\\Users\\\\dunca\\\\AppData\\\\Local\\\\Temp\\\\tmpc7jzikac.pdf'}, page_content='Color\\n\\nwhite\\n\\nScore\\n\\nShape\\n\\nCAPSULE\\n\\nSize\\n\\nFlavor\\n\\nImprint Code\\n\\nContains\\n\\nPackaging\\n\\n# Item Code\\n\\nPackage Description\\n\\n1\\n\\nNDC:70505- 220-60\\n\\n1 in 1 CARTON\\n\\n1\\n\\n60 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product\\n\\nMarketing Information\\n\\nMarketing Category\\n\\nApplication Number or Monograph Citation\\n\\nANDA\\n\\nANDA212390\\n\\nLabeler - Analog Pharma (080132990)\\n\\nRevised: 12/2024\\n\\nMarketing Start Date\\n\\n05/08/2023\\n\\nMarketing Start Date\\n\\n05/08/2023\\n\\nno score\\n\\n18mm\\n\\n20;logo\\n\\nMarketing End Date\\n\\nMarketing End Date\\n\\nAnalog Pharma')]"
      ]
     },
     "execution_count": 2,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "\n",
    "import requests\n",
    "import tempfile\n",
    "from langchain_community.document_loaders import UnstructuredPDFLoader\n",
    "from langchain.text_splitter import RecursiveCharacterTextSplitter\n",
    "\n",
    "# PDF URL from DailyMed\n",
    "url = \"https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=645c8387-30d5-4a86-a5d8-2f6b5df6d5f0&type=pdf\"\n",
    "\n",
    "# Download to temp file\n",
    "response = requests.get(url)\n",
    "response.raise_for_status()\n",
    "\n",
    "with tempfile.NamedTemporaryFile(delete=False, suffix=\".pdf\") as tmp_file:\n",
    "    tmp_file.write(response.content)\n",
    "    temp_pdf_path = tmp_file.name\n",
    "\n",
    "# Load and split\n",
    "loader = UnstructuredPDFLoader(temp_pdf_path)\n",
    "text_splitter = RecursiveCharacterTextSplitter(chunk_size=1000, chunk_overlap=20)\n",
    "documents = loader.load_and_split(text_splitter)\n",
    "\n",
    "documents\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "46"
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(documents)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Load the content in a vector store ###"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "from huggingface_hub import login\n",
    "\n",
    "login(token=os.getenv(\"TOKEN\"))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "C:\\Users\\dunca\\AppData\\Local\\Temp\\ipykernel_6724\\3943883326.py:4: LangChainDeprecationWarning: The class `HuggingFaceEmbeddings` was deprecated in LangChain 0.2.2 and will be removed in 1.0. An updated version of the class exists in the :class:`~langchain-huggingface package and should be used instead. To use it run `pip install -U :class:`~langchain-huggingface` and import as `from :class:`~langchain_huggingface import HuggingFaceEmbeddings``.\n",
      "  embedding_model = HuggingFaceEmbeddings(model_name=\"sentence-transformers/paraphrase-MiniLM-L3-v2\")\n",
      "c:\\Users\\dunca\\OneDrive\\Desktop\\Disertation\\LLM\\venv\\lib\\site-packages\\pydantic\\_migration.py:283: UserWarning: `pydantic.error_wrappers:ValidationError` has been moved to `pydantic:ValidationError`.\n",
      "  warnings.warn(f'`{import_path}` has been moved to `{new_location}`.')\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<langchain_community.vectorstores.docarray.in_memory.DocArrayInMemorySearch object at 0x0000020E4A12F1C0>\n"
     ]
    }
   ],
   "source": [
    "from langchain.embeddings import HuggingFaceEmbeddings\n",
    "from langchain_community.vectorstores import DocArrayInMemorySearch\n",
    "\n",
    "embedding_model = HuggingFaceEmbeddings(model_name=\"sentence-transformers/paraphrase-MiniLM-L3-v2\")  \n",
    "\n",
    "vectorstore = DocArrayInMemorySearch.from_documents(documents, embedding=embedding_model)\n",
    "print(vectorstore)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Create a knowledge base ###"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>text</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NITISINONE- nitisinone capsule Analog Pharma\\n...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>The recommended starting dosage is 0.5 mg/kg o...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Elevated Plasma Tyrosine Levels, Ocular Sympto...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>ADVERSE REACTIONS\\n\\nMost common adverse react...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Revised: 6/2023\\n\\nFULL PRESCRIBING INFORMATIO...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>Nitisinone capsules are indicated for the trea...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>Monitor plasma and/or urine succinylacetone co...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>levels below 500 micromol/L by dietary restric...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>2.2 Administration\\n\\nAdministration of Nitisi...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>Nitisinone is an inhibitor of 4-hydroxyphenyl-...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                text\n",
       "0  NITISINONE- nitisinone capsule Analog Pharma\\n...\n",
       "1  The recommended starting dosage is 0.5 mg/kg o...\n",
       "2  Elevated Plasma Tyrosine Levels, Ocular Sympto...\n",
       "3  ADVERSE REACTIONS\\n\\nMost common adverse react...\n",
       "4  Revised: 6/2023\\n\\nFULL PRESCRIBING INFORMATIO...\n",
       "5  Nitisinone capsules are indicated for the trea...\n",
       "6  Monitor plasma and/or urine succinylacetone co...\n",
       "7  levels below 500 micromol/L by dietary restric...\n",
       "8  2.2 Administration\\n\\nAdministration of Nitisi...\n",
       "9  Nitisinone is an inhibitor of 4-hydroxyphenyl-..."
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import pandas as pd\n",
    "\n",
    "df = pd.DataFrame([d.page_content for d in documents], columns=[\"text\"])\n",
    "\n",
    "df.head(10)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "import giskard\n",
    "\n",
    "# Setarea endpointului local pentru Ollama\n",
    "api_base = \"http://localhost:11434\"\n",
    "\n",
    "# Setează modelul principal LLM (ex: Qwen2.5 sau llama2, în funcție de ce ai instalat în Ollama)\n",
    "giskard.llm.set_llm_model(\"ollama/mistral\", api_base=\"http://localhost:11434\", disable_structured_output=True)\n",
    "\n",
    "# Setează modelul de embedding (ex: nomic-embed-text, disponibil prin Ollama)\n",
    "giskard.llm.set_embedding_model(\"ollama/nomic-embed-text\", api_base=api_base)\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [],
   "source": [
    "import nest_asyncio\n",
    "nest_asyncio.apply()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [],
   "source": [
    "from giskard.rag import KnowledgeBase\n",
    "\n",
    "knowledge_base = KnowledgeBase(df)\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Generate the Test set ###"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "2025-05-30 21:07:19,128 pid:6724 MainThread giskard.rag  INFO     Finding topics in the knowledge base.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "c:\\Users\\dunca\\OneDrive\\Desktop\\Disertation\\LLM\\venv\\lib\\site-packages\\sklearn\\utils\\deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "c:\\Users\\dunca\\OneDrive\\Desktop\\Disertation\\LLM\\venv\\lib\\site-packages\\umap\\umap_.py:2462: UserWarning: n_neighbors is larger than the dataset size; truncating to X.shape[0] - 1\n",
      "  warn(\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "2025-05-30 21:08:52,916 pid:6724 MainThread giskard.rag  INFO     Found 4 topics in the knowledge base.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Generating questions: 100%|██████████| 1/1 [00:39<00:00, 39.51s/it]\n"
     ]
    }
   ],
   "source": [
    "from giskard.rag import generate_testset\n",
    "\n",
    "testset = generate_testset(\n",
    "    knowledge_base,\n",
    "    num_questions=1,\n",
    "    agent_description=\"A chatbot answering questions about medicine drugs\",\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Question 1: What are the reproductive risks associated with nitisinone in animals?\n",
      "Reference answer: In animal reproduction studies, nitisinone was shown to cause incomplete skeletal ossification of fetal bones and decreased pup survival at doses 0.4 times the recommended initial dose in mice. In addition, increased gestational length was observed at doses 4 times the recommended initial dose in mice, and maternal toxicity and incomplete skeletal ossification of fetal bones were seen at doses 1.6 times the recommended initial dose in rabbits.\n",
      "Reference context:\n",
      "Document 19: Data\n",
      "\n",
      "Animal Data\n",
      "\n",
      "Reproduction studies have been performed in mice at oral doses of about 0.4, 4 and 20 times the recommended initial dose (1 mg/kg/day) and in rabbits at oral doses of about 1.6, 4 and 8 times the recommended initial dose based on the body surface area. In mice, nitisinone has been shown to cause incomplete skeletal ossification of fetal bones at 0.4, 4 and 20 times the recommended initial dose, increased gestational length at 4 and 20 times the recommended initial dose, and decreased pup survival at 0.4 times the recommended initial dose based on the body surface area. In rabbits, nitisinone caused incomplete skeletal ossification of fetal bones at 1.6, 4 and 8 times the recommended initial dose based on the body surface area.\n",
      "\n",
      "8.2 Lactation\n",
      "\n",
      "Risk Summary\n",
      "\n",
      "Document 17: Risk Summary\n",
      "\n",
      "Limited available data with nitisinone use in pregnant women are not sufficient to determine a drug-associated risk of adverse developmental outcomes. Animal reproduction studies have been conducted for nitisinone. In these studies, nitisinone was administered to mice and rabbits during organogenesis with oral doses of nitisinone up to 20 and 8 times respectively, the recommended initial dose of 1 mg/kg/day. In mice, nitisinone caused incomplete skeletal ossification of fetal bones and decreased pup survival at doses 0.4 times the recommended initial dose, and increased gestational length at doses 4 times the recommended initial dose. In rabbits, nitisinone caused maternal toxicity and incomplete skeletal ossification of fetal bones at doses 1.6 times the recommended initial dose [see Data].\n",
      "------------------------------\n",
      "\n"
     ]
    }
   ],
   "source": [
    "test_set_df = testset.to_pandas()\n",
    "\n",
    "for index, row in enumerate(test_set_df.head(3).iterrows()):\n",
    "    print(f\"Question {index + 1}: {row[1]['question']}\")\n",
    "    print(f\"Reference answer: {row[1]['reference_answer']}\")\n",
    "    print(\"Reference context:\")\n",
    "    print(row[1]['reference_context'])\n",
    "    print(\"------------------------------\", end=\"\\n\\n\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [],
   "source": [
    "testset.save(\"test-set.jsonl\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "Answer the question based on the context below. If you can't\n",
      "answer the question, reply \"I don't know\".\n",
      "\n",
      "Context: Here is some context\n",
      "\n",
      "Question: Here is a question\n",
      "\n"
     ]
    }
   ],
   "source": [
    "from langchain.prompts import PromptTemplate\n",
    "\n",
    "template = \"\"\"\n",
    "Answer the question based on the context below. If you can't\n",
    "answer the question, reply \"I don't know\".\n",
    "\n",
    "Context: {context}\n",
    "\n",
    "Question: {question}\n",
    "\"\"\"\n",
    "\n",
    "prompt = PromptTemplate.from_template(template)\n",
    "print(prompt.format(context=\"Here is some context\", question=\"Here is a question\"))\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain_ollama import OllamaLLM,OllamaEmbeddings \n",
    "from langchain_core.output_parsers import StrOutputParser\n",
    "from operator import itemgetter\n",
    "\n",
    "model = OllamaLLM(model=MODEL)\n",
    "\n",
    "chain = (\n",
    "    {\n",
    "        \"context\": itemgetter(\"question\") | vectorstore.as_retriever(),\n",
    "        \"question\": itemgetter(\"question\"),\n",
    "    }\n",
    "    | prompt\n",
    "    | model\n",
    "    | StrOutputParser()\n",
    ")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [],
   "source": [
    "def answer_fn(question, history=None):\n",
    "    return chain.invoke({\"question\": question})    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Asking questions to the agent: 100%|██████████| 1/1 [01:15<00:00, 75.33s/it]\n",
      "CorrectnessMetric evaluation: 100%|██████████| 1/1 [00:20<00:00, 20.80s/it]\n"
     ]
    }
   ],
   "source": [
    "from giskard.rag import evaluate\n",
    "\n",
    "report = evaluate(answer_fn, testset=testset, knowledge_base=knowledge_base)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "    <style>\n",
       "        .bk-notebook-logo {\n",
       "            display: block;\n",
       "            width: 20px;\n",
       "            height: 20px;\n",
       "            background-image: url(data:image/png;base64,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);\n",
       "        }\n",
       "    </style>\n",
       "    <div>\n",
       "        <a href=\"https://bokeh.org\" target=\"_blank\" class=\"bk-notebook-logo\"></a>\n",
       "        <span id=\"aea9a32b-082c-4957-8c37-23fab5b5125b\">Loading BokehJS ...</span>\n",
       "    </div>\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/javascript": "'use strict';\n(function(root) {\n  function now() {\n    return new Date();\n  }\n\n  const force = true;\n\n  if (typeof root._bokeh_onload_callbacks === \"undefined\" || force === true) {\n    root._bokeh_onload_callbacks = [];\n    root._bokeh_is_loading = undefined;\n  }\n\nconst JS_MIME_TYPE = 'application/javascript';\n  const HTML_MIME_TYPE = 'text/html';\n  const EXEC_MIME_TYPE = 'application/vnd.bokehjs_exec.v0+json';\n  const CLASS_NAME = 'output_bokeh rendered_html';\n\n  /**\n   * Render data to the DOM node\n   */\n  function render(props, node) {\n    const script = document.createElement(\"script\");\n    node.appendChild(script);\n  }\n\n  /**\n   * Handle when an output is cleared or removed\n   */\n  function handleClearOutput(event, handle) {\n    function drop(id) {\n      const view = Bokeh.index.get_by_id(id)\n      if (view != null) {\n        view.model.document.clear()\n        Bokeh.index.delete(view)\n      }\n    }\n\n    const cell = handle.cell;\n\n    const id = cell.output_area._bokeh_element_id;\n    const server_id = cell.output_area._bokeh_server_id;\n\n    // Clean up Bokeh references\n    if (id != null) {\n      drop(id)\n    }\n\n    if (server_id !== undefined) {\n      // Clean up Bokeh references\n      const cmd_clean = \"from bokeh.io.state import curstate; print(curstate().uuid_to_server['\" + server_id + \"'].get_sessions()[0].document.roots[0]._id)\";\n      cell.notebook.kernel.execute(cmd_clean, {\n        iopub: {\n          output: function(msg) {\n            const id = msg.content.text.trim()\n            drop(id)\n          }\n        }\n      });\n      // Destroy server and session\n      const cmd_destroy = \"import bokeh.io.notebook as ion; ion.destroy_server('\" + server_id + \"')\";\n      cell.notebook.kernel.execute(cmd_destroy);\n    }\n  }\n\n  /**\n   * Handle when a new output is added\n   */\n  function handleAddOutput(event, handle) {\n    const output_area = handle.output_area;\n    const output = handle.output;\n\n    // limit handleAddOutput to display_data with EXEC_MIME_TYPE content only\n    if ((output.output_type != \"display_data\") || (!Object.prototype.hasOwnProperty.call(output.data, EXEC_MIME_TYPE))) {\n      return\n    }\n\n    const toinsert = output_area.element.find(\".\" + CLASS_NAME.split(' ')[0]);\n\n    if (output.metadata[EXEC_MIME_TYPE][\"id\"] !== undefined) {\n      toinsert[toinsert.length - 1].firstChild.textContent = output.data[JS_MIME_TYPE];\n      // store reference to embed id on output_area\n      output_area._bokeh_element_id = output.metadata[EXEC_MIME_TYPE][\"id\"];\n    }\n    if (output.metadata[EXEC_MIME_TYPE][\"server_id\"] !== undefined) {\n      const bk_div = document.createElement(\"div\");\n      bk_div.innerHTML = output.data[HTML_MIME_TYPE];\n      const script_attrs = bk_div.children[0].attributes;\n      for (let i = 0; i < script_attrs.length; i++) {\n        toinsert[toinsert.length - 1].firstChild.setAttribute(script_attrs[i].name, script_attrs[i].value);\n        toinsert[toinsert.length - 1].firstChild.textContent = bk_div.children[0].textContent\n      }\n      // store reference to server id on output_area\n      output_area._bokeh_server_id = output.metadata[EXEC_MIME_TYPE][\"server_id\"];\n    }\n  }\n\n  function register_renderer(events, OutputArea) {\n\n    function append_mime(data, metadata, element) {\n      // create a DOM node to render to\n      const toinsert = this.create_output_subarea(\n        metadata,\n        CLASS_NAME,\n        EXEC_MIME_TYPE\n      );\n      this.keyboard_manager.register_events(toinsert);\n      // Render to node\n      const props = {data: data, metadata: metadata[EXEC_MIME_TYPE]};\n      render(props, toinsert[toinsert.length - 1]);\n      element.append(toinsert);\n      return toinsert\n    }\n\n    /* Handle when an output is cleared or removed */\n    events.on('clear_output.CodeCell', handleClearOutput);\n    events.on('delete.Cell', handleClearOutput);\n\n    /* Handle when a new output is added */\n    events.on('output_added.OutputArea', handleAddOutput);\n\n    /**\n     * Register the mime type and append_mime function with output_area\n     */\n    OutputArea.prototype.register_mime_type(EXEC_MIME_TYPE, append_mime, {\n      /* Is output safe? */\n      safe: true,\n      /* Index of renderer in `output_area.display_order` */\n      index: 0\n    });\n  }\n\n  // register the mime type if in Jupyter Notebook environment and previously unregistered\n  if (root.Jupyter !== undefined) {\n    const events = require('base/js/events');\n    const OutputArea = require('notebook/js/outputarea').OutputArea;\n\n    if (OutputArea.prototype.mime_types().indexOf(EXEC_MIME_TYPE) == -1) {\n      register_renderer(events, OutputArea);\n    }\n  }\n  if (typeof (root._bokeh_timeout) === \"undefined\" || force === true) {\n    root._bokeh_timeout = Date.now() + 5000;\n    root._bokeh_failed_load = false;\n  }\n\n  const NB_LOAD_WARNING = {'data': {'text/html':\n     \"<div style='background-color: #fdd'>\\n\"+\n     \"<p>\\n\"+\n     \"BokehJS does not appear to have successfully loaded. If loading BokehJS from CDN, this \\n\"+\n     \"may be due to a slow or bad network connection. Possible fixes:\\n\"+\n     \"</p>\\n\"+\n     \"<ul>\\n\"+\n     \"<li>re-rerun `output_notebook()` to attempt to load from CDN again, or</li>\\n\"+\n     \"<li>use INLINE resources instead, as so:</li>\\n\"+\n     \"</ul>\\n\"+\n     \"<code>\\n\"+\n     \"from bokeh.resources import INLINE\\n\"+\n     \"output_notebook(resources=INLINE)\\n\"+\n     \"</code>\\n\"+\n     \"</div>\"}};\n\n  function display_loaded(error = null) {\n    const el = document.getElementById(\"aea9a32b-082c-4957-8c37-23fab5b5125b\");\n    if (el != null) {\n      const html = (() => {\n        if (typeof root.Bokeh === \"undefined\") {\n          if (error == null) {\n            return \"BokehJS is loading ...\";\n          } else {\n            return \"BokehJS failed to load.\";\n          }\n        } else {\n          const prefix = `BokehJS ${root.Bokeh.version}`;\n          if (error == null) {\n            return `${prefix} successfully loaded.`;\n          } else {\n            return `${prefix} <b>encountered errors</b> while loading and may not function as expected.`;\n          }\n        }\n      })();\n      el.innerHTML = html;\n\n      if (error != null) {\n        const wrapper = document.createElement(\"div\");\n        wrapper.style.overflow = \"auto\";\n        wrapper.style.height = \"5em\";\n        wrapper.style.resize = \"vertical\";\n        const content = document.createElement(\"div\");\n        content.style.fontFamily = \"monospace\";\n        content.style.whiteSpace = \"pre-wrap\";\n        content.style.backgroundColor = \"rgb(255, 221, 221)\";\n        content.textContent = error.stack ?? error.toString();\n        wrapper.append(content);\n        el.append(wrapper);\n      }\n    } else if (Date.now() < root._bokeh_timeout) {\n      setTimeout(() => display_loaded(error), 100);\n    }\n  }\n\n  function run_callbacks() {\n    try {\n      root._bokeh_onload_callbacks.forEach(function(callback) {\n        if (callback != null)\n          callback();\n      });\n    } finally {\n      delete root._bokeh_onload_callbacks\n    }\n    console.debug(\"Bokeh: all callbacks have finished\");\n  }\n\n  function load_libs(css_urls, js_urls, callback) {\n    if (css_urls == null) css_urls = [];\n    if (js_urls == null) js_urls = [];\n\n    root._bokeh_onload_callbacks.push(callback);\n    if (root._bokeh_is_loading > 0) {\n      console.debug(\"Bokeh: BokehJS is being loaded, scheduling callback at\", now());\n      return null;\n    }\n    if (js_urls == null || js_urls.length === 0) {\n      run_callbacks();\n      return null;\n    }\n    console.debug(\"Bokeh: BokehJS not loaded, scheduling load and callback at\", now());\n    root._bokeh_is_loading = css_urls.length + js_urls.length;\n\n    function on_load() {\n      root._bokeh_is_loading--;\n      if (root._bokeh_is_loading === 0) {\n        console.debug(\"Bokeh: all BokehJS libraries/stylesheets loaded\");\n        run_callbacks()\n      }\n    }\n\n    function on_error(url) {\n      console.error(\"failed to load \" + url);\n    }\n\n    for (let i = 0; i < css_urls.length; i++) {\n      const url = css_urls[i];\n      const element = document.createElement(\"link\");\n      element.onload = on_load;\n      element.onerror = on_error.bind(null, url);\n      element.rel = \"stylesheet\";\n      element.type = \"text/css\";\n      element.href = url;\n      console.debug(\"Bokeh: injecting link tag for BokehJS stylesheet: \", url);\n      document.body.appendChild(element);\n    }\n\n    for (let i = 0; i < js_urls.length; i++) {\n      const url = js_urls[i];\n      const element = document.createElement('script');\n      element.onload = on_load;\n      element.onerror = on_error.bind(null, url);\n      element.async = false;\n      element.src = url;\n      console.debug(\"Bokeh: injecting script tag for BokehJS library: \", url);\n      document.head.appendChild(element);\n    }\n  };\n\n  function inject_raw_css(css) {\n    const element = document.createElement(\"style\");\n    element.appendChild(document.createTextNode(css));\n    document.body.appendChild(element);\n  }\n\n  const js_urls = [\"https://cdn.bokeh.org/bokeh/release/bokeh-3.4.3.min.js\", \"https://cdn.bokeh.org/bokeh/release/bokeh-gl-3.4.3.min.js\", \"https://cdn.bokeh.org/bokeh/release/bokeh-widgets-3.4.3.min.js\", \"https://cdn.bokeh.org/bokeh/release/bokeh-tables-3.4.3.min.js\", \"https://cdn.bokeh.org/bokeh/release/bokeh-mathjax-3.4.3.min.js\"];\n  const css_urls = [];\n\n  const inline_js = [    function(Bokeh) {\n      Bokeh.set_log_level(\"info\");\n    },\nfunction(Bokeh) {\n    }\n  ];\n\n  function run_inline_js() {\n    if (root.Bokeh !== undefined || force === true) {\n      try {\n            for (let i = 0; i < inline_js.length; i++) {\n      inline_js[i].call(root, root.Bokeh);\n    }\n\n      } catch (error) {display_loaded(error);throw error;\n      }if (force === true) {\n        display_loaded();\n      }} else if (Date.now() < root._bokeh_timeout) {\n      setTimeout(run_inline_js, 100);\n    } else if (!root._bokeh_failed_load) {\n      console.log(\"Bokeh: BokehJS failed to load within specified timeout.\");\n      root._bokeh_failed_load = true;\n    } else if (force !== true) {\n      const cell = $(document.getElementById(\"aea9a32b-082c-4957-8c37-23fab5b5125b\")).parents('.cell').data().cell;\n      cell.output_area.append_execute_result(NB_LOAD_WARNING)\n    }\n  }\n\n  if (root._bokeh_is_loading === 0) {\n    console.debug(\"Bokeh: BokehJS loaded, going straight to plotting\");\n    run_inline_js();\n  } else {\n    load_libs(css_urls, js_urls, function() {\n      console.debug(\"Bokeh: BokehJS plotting callback run at\", now());\n      run_inline_js();\n    });\n  }\n}(window));",
      "application/vnd.bokehjs_load.v0+json": ""
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<!DOCTYPE html>\n",
       "\n",
       "\n",
       "<style>\n",
       "    body{\n",
       "  background: #18181B;\n",
       "}\n",
       "\n",
       ".main{\n",
       "  font-family: \"Noto Sans\", ui-sans-serif, system-ui, -apple-system, BlinkMacSystemFont, \"Segoe UI\", Roboto, \"Helvetica Neue\", Arial, sans-serif, \"Apple Color Emoji\", \"Segoe UI Emoji\", \"Segoe UI Symbol\", \"Noto Color Emoji\";\n",
       "  color: #FDFDFD;\n",
       "}\n",
       "\n",
       "h1 {\n",
       "  font-size: 2.5rem;\n",
       "  color: white;\n",
       "}\n",
       "\n",
       "h3 {\n",
       "  font-size: 1.5rem;\n",
       "  background: #0c087c;\n",
       "  padding: 10px;\n",
       "  margin: 0px;\n",
       "  border: 1px solid #6b7280;}\n",
       "\n",
       ".extended-title{\n",
       "  width:100%;\n",
       "}\n",
       "\n",
       "#gsk-overview{\n",
       "  display:flex;\n",
       "}\n",
       "\n",
       "h4 {\n",
       "  font-size: 1rem;\n",
       "  background: #27272A;\n",
       "  padding: 10px;\n",
       "  margin: 0px;\n",
       "  border-bottom: 1px solid #6b7280;\n",
       "}\n",
       "\n",
       "h2 {\n",
       "  font-size: 1.5rem;\n",
       "  margin-top: 3px;\n",
       "  color:#000000;\n",
       "}\n",
       "\n",
       ".header{\n",
       "  display: flex;\n",
       "  justify-content: center;\n",
       "  align-items: center;\n",
       "}\n",
       ".header > * {\n",
       "  margin-inline: 20px;\n",
       "}\n",
       "\n",
       ".flex-row {\n",
       "  display: flex;\n",
       "  flex-direction: row;\n",
       "  padding:10px;\n",
       "  border: 1px solid #27272A;\n",
       "}\n",
       "\n",
       ".flex-row>div {\n",
       "  flex: auto;\n",
       "  box-sizing: border-box;\n",
       "  display: flex;\n",
       "  flex-direction: column;\n",
       "  justify-content: center;\n",
       "  align-items: center;\n",
       "}\n",
       "\n",
       "progress[value] {\n",
       "  --background: #6D6D6D;\n",
       "  -webkit-appearance: none;\n",
       "  -moz-appearance: none;\n",
       "  appearance: none;\n",
       "  border: none;\n",
       "  height: 4px;\n",
       "  margin: 0 10px;\n",
       "  border-radius: 10em;\n",
       "  background: var(--background);\n",
       "}\n",
       "\n",
       "progress[value]::-webkit-progress-bar {\n",
       "  border-radius: 10em;\n",
       "  background: var(--background);\n",
       "}\n",
       "\n",
       "progress[value]::-webkit-progress-value {\n",
       "  border-radius: 10em;\n",
       "  background: var(--color);\n",
       "}\n",
       "\n",
       "progress[value]::-moz-progress-bar {\n",
       "  border-radius: 10em;\n",
       "  background: var(--color);\n",
       "}\n",
       "\n",
       "label {\n",
       "  font-size: 20px;\n",
       "  font-weight: bold;\n",
       "  display: block;\n",
       "  margin: 20px 0;\n",
       "}\n",
       "\n",
       ".tab {\n",
       "  overflow: hidden;\n",
       "  border: 1px solid #27272A;\n",
       "  background-color: #27272A;\n",
       "}\n",
       "\n",
       ".tab button {\n",
       "  background-color: inherit;\n",
       "  float: left;\n",
       "  border: none;\n",
       "  outline: none;\n",
       "  cursor: pointer;\n",
       "  padding: 14px 16px;\n",
       "  transition: 0.3s;\n",
       "  color: #ffffff;\n",
       "  font-size:1.2rem;\n",
       "}\n",
       "\n",
       ".tab div {\n",
       "  background-color: inherit;\n",
       "  float: left;\n",
       "  border: none;\n",
       "  outline: none;\n",
       "  cursor: pointer;\n",
       "  padding: 14px 16px;\n",
       "  transition: 0.3s;\n",
       "  color: #ffffff;\n",
       "  font-size: 1.2rem;\n",
       "}\n",
       "\n",
       ".tab button:hover {\n",
       "  background-color: #18181B;\n",
       "}\n",
       "\n",
       ".tab-title{\n",
       "  font-size: 1.5rem;\n",
       "  font-weight: bold;\n",
       "  margin-bottom:-5px;\n",
       "}\n",
       "\n",
       ".tab button.active {\n",
       "  background-color: #18181B;\n",
       "  border-top: 1px solid #6b7280;\n",
       "  border-bottom: 1px solid #18181B;\n",
       "  border-left: 1px solid #6b7280;\n",
       "  border-right: 1px solid #6b7280;\n",
       "}\n",
       "\n",
       ".tabcontent {\n",
       "  display: none;\n",
       "  padding: 6px 12px;\n",
       "  background: #18181B;\n",
       "  border: 1px solid #27272A;\n",
       "  border-top: 1px solid #6b7280;\n",
       "  margin-top: -2px;\n",
       "}\n",
       "\n",
       "#gsk-advice {\n",
       "  display: flex;\n",
       "  justify-content: center;\n",
       "}\n",
       "\n",
       "#gsk-metrics{\n",
       "  width:100%;\n",
       "}\n",
       "\n",
       "#recommendation {\n",
       "  margin-top: 20px;\n",
       "  padding: 20px;\n",
       "  border-radius: 10px;\n",
       "  background-color: #e1ce86;\n",
       "  color: #27272A;\n",
       "  width:95%;\n",
       "  box-shadow: 0 4px 8px 0 #000000, 0 6px 20px 0 #000000;\n",
       "  font-size: 12pt;\n",
       "}\n",
       "\n",
       ".separator {\n",
       "  margin: 20px 0;\n",
       "}\n",
       "\n",
       ".separator-border {\n",
       "  margin: 20px 0;\n",
       "  border-bottom: 1px solid #6b7280;\n",
       "}\n",
       "\n",
       "#gsk-rag{\n",
       "  margin: 32px 28px;\n",
       "  padding: 12px 24px;\n",
       "  background-color: #111516;\n",
       "}\n",
       "\n",
       ".section-container {\n",
       "  margin-bottom: 32px;\n",
       "}\n",
       "\n",
       "  .components-container {\n",
       "    display: flex;\n",
       "    flex-flow: row wrap;\n",
       "    align-items: flex-start;\n",
       "    gap: 0 32px;\n",
       "  }\n",
       "\n",
       "    .component-card {\n",
       "      background-color: #14191B;\n",
       "      border-radius: 16px;\n",
       "      padding: 28px 32px 32px 32px;\n",
       "      display: flex;\n",
       "      flex-flow: column;\n",
       "      align-items: center;\n",
       "      margin-top: 32px;\n",
       "      flex-grow: 1;\n",
       "    }\n",
       "\n",
       "    .component-title {\n",
       "      font-size: 12px;\n",
       "      font-weight: 500;\n",
       "      color: #B1B1B1;\n",
       "      padding-bottom: 8px;\n",
       "    }\n",
       "\n",
       "    .component-value {\n",
       "      font-size: 32px;\n",
       "      font-weight: 500;\n",
       "      padding-bottom: 12px;\n",
       "    }\n",
       "      \n",
       "      .text-green {\n",
       "        color: #04B543;\n",
       "      }\n",
       "      \n",
       "      .text-orange {\n",
       "        color: #E76E0F;\n",
       "      }\n",
       "      \n",
       "      .text-red {\n",
       "        color: #EA3829;\n",
       "      }\n",
       "\n",
       "      .tooltip {\n",
       "        position: relative;\n",
       "        display: inline-block;\n",
       "      }\n",
       "\n",
       "      .tooltip .tooltiptext {\n",
       "        visibility: hidden;\n",
       "        width: 120px;\n",
       "        background-color: #464646;\n",
       "        color: #E6E6E6;\n",
       "        text-align: center;\n",
       "        border-radius: 6px;\n",
       "        position: absolute;\n",
       "        z-index: 1;\n",
       "        top: 150%;\n",
       "        left: 50%;\n",
       "        margin-left: -60px;\n",
       "        font-size: 12px;\n",
       "        padding: 12px;\n",
       "      }\n",
       "      \n",
       "      .tooltip .tooltiptext::after {\n",
       "        content: \"\";\n",
       "        position: absolute;\n",
       "        bottom: 100%;\n",
       "        left: 50%;\n",
       "        margin-left: -5px;\n",
       "        border-width: 5px;\n",
       "        border-style: solid;\n",
       "        border-color: transparent transparent black transparent;\n",
       "      }\n",
       "      \n",
       "      .tooltip:hover .tooltiptext {\n",
       "        visibility: visible;\n",
       "      }\n",
       "\n",
       "    .overall-card {\n",
       "      background-color: #026836;\n",
       "      border-radius: 16px;\n",
       "      padding: 28px 32px 32px 32px;\n",
       "      display: flex;\n",
       "      flex-flow: column;\n",
       "      align-items: center;\n",
       "      justify-content: center;\n",
       "      margin-top: 32px;\n",
       "      flex-grow: 1;\n",
       "    }\n",
       "  \n",
       "    .overall-title {\n",
       "      font-size: 12px;\n",
       "      font-weight: 500;\n",
       "      color: #E6E6E6;\n",
       "      padding: 14px 0 8px 0;\n",
       "      text-transform: uppercase;\n",
       "     }\n",
       "  \n",
       "    .overall-value {\n",
       "      font-size: 32px;\n",
       "      font-weight: 500;\n",
       "      padding-bottom: 12px;\n",
       "      color: #E6E6E6;\n",
       "    }\n",
       "\n",
       ".section-title {\n",
       "  font-size: 12px;\n",
       "  color: #B1B1B1;\n",
       "  margin-bottom: 20px;\n",
       "  text-align: left;\n",
       "  width: 100%;\n",
       "}\n",
       "\n",
       ".section-content {\n",
       "  color: #E6E6E6;\n",
       "  font-size: 20px;\n",
       "  line-height: 1.5;\n",
       "}\n",
       "\n",
       ".section-card {\n",
       "  background-color: #14191B;\n",
       "  border-radius: 16px;\n",
       "  padding: 28px 32px 32px 32px;\n",
       "  display: flex;\n",
       "  flex-flow: column;\n",
       "  align-items: center;\n",
       "}\n",
       "\n",
       ".correctness-indicator{\n",
       "  padding: 20px;\n",
       "  border-radius: 50px;\n",
       "  font-size: 16pt;\n",
       "  box-shadow: 0 4px 8px 0 #000000, 0 6px 20px 0 #000000;\n",
       "  text-align: center;\n",
       "}\n",
       "\n",
       ".metric-title{\n",
       "  margin: -2px;\n",
       "  border-bottom: none;\n",
       "}\n",
       "\n",
       ".hist-row {\n",
       "  display: flex;\n",
       "  flex-direction: row;\n",
       "  padding: 10px;\n",
       "  justify-content: space-around;\n",
       "  width: 85%;\n",
       "}\n",
       "\n",
       ".hist-row>div {\n",
       "  flex: auto;\n",
       "  box-sizing: border-box;\n",
       "  display: flex;\n",
       "  flex-direction: column;\n",
       "  justify-content: center;\n",
       "  align-items: center;\n",
       "  padding-left: 1%;\n",
       "  padding-right: 1%;\n",
       "}\n",
       "\n",
       ".tab-row{\n",
       "  display: flex;\n",
       "  flex-direction: column;\n",
       "  align-items: center;\n",
       "}\n",
       "\n",
       "#component-table{\n",
       "  width:50%;\n",
       "  margin-top: 10px;\n",
       "}\n",
       "\n",
       ".green{\n",
       "  background-color: #0a980a;\n",
       "}\n",
       "\n",
       ".orange {\n",
       "  background-color: #e5b62a;\n",
       "}\n",
       "\n",
       ".red {\n",
       "  background-color: #ba0e0e;\n",
       "}\n",
       "\n",
       ".progress-green {\n",
       "  --color: #04B543;\n",
       "}\n",
       "\n",
       ".progress-orange {\n",
       "  --color: #E76E0F;\n",
       "}\n",
       "\n",
       ".progress-red {\n",
       "  --color: #EA3829;\n",
       "}\n",
       "\n",
       ".corr-plot{\n",
       "  flex: 1;\n",
       "  padding-left: 2%;\n",
       "}\n",
       "\n",
       ".tooltip-text {\n",
       "  position: absolute;\n",
       "  display: none;\n",
       "  visibility: hidden;\n",
       "  z-index: 1;\n",
       "  top: 100%;\n",
       "  left: 0%;\n",
       "  width: 100%;\n",
       "  color: white;\n",
       "  font-size: 12px;\n",
       "  background-color: #2d3d4c;\n",
       "  border-radius: 10px;\n",
       "  padding: 10px 15px 10px 15px;\n",
       "}\n",
       "\n",
       "#fade {\n",
       "  opacity: 1;\n",
       "  transition: opacity 0.5s;\n",
       "}\n",
       "\n",
       "#delay {\n",
       "  opacity: 0;\n",
       "  transition: opacity 0.2s;\n",
       "  transition-delay: 1s;\n",
       "}\n",
       "\n",
       "td {\n",
       "  position: relative;\n",
       "}\n",
       "\n",
       "tr:hover .tooltip-text {\n",
       "  display: block;\n",
       "  visibility: visible;\n",
       "}\n",
       "\n",
       ".tr:hover #fade {\n",
       "  opacity: 1;\n",
       "}\n",
       "\n",
       ".tr:hover #delay {\n",
       "  opacity: 1;\n",
       "}\n",
       "\n",
       ".callout {\n",
       "  padding: 0.5rem 1rem 0.5rem 3rem;\n",
       "  background: #D9EDF9;\n",
       "  border: 3px solid #0088D1;\n",
       "  color: #272eb5;\n",
       "  position: relative;\n",
       "  max-width: 40rem;\n",
       "  border-radius: 10px;\n",
       "  margin-top: 10%;\n",
       "  font-size: 11pt;\n",
       "}\n",
       "\n",
       ".callout-icon {\n",
       "  content: \"\";\n",
       "\n",
       "  /* SVG via a data URI! */\n",
       "  background-size: cover;\n",
       "  width: 1.5rem;\n",
       "  height: 1.5rem;\n",
       "  display: block;\n",
       "  position: absolute;\n",
       "  left: 0.9rem;\n",
       "  top: 1.1rem;\n",
       "}\n",
       "\n",
       ".callout-icon svg{\n",
       "  fill: #016ca7;\n",
       "}\n",
       ".callout p+p {\n",
       "  margin-top: 1em;\n",
       "}\n",
       "\n",
       ".callout a {\n",
       "  color: #272eb5;\n",
       "  font-weight: bold;\n",
       "}\n",
       "\n",
       "#gsk-logo {\n",
       "  padding-top: 10px;\n",
       "}\n",
       "</style>\n",
       "<script src=\"https://cdn.bokeh.org/bokeh/release/bokeh-3.3.4.min.js\" integrity=\"sha384-5QIrjQuyo4I/x6DK/Sau33lcA3hT2TCZGr9vbk+2ebd7Da6FnR1amdM+9B5xOrSf\" crossorigin=\"anonymous\"></script>\n",
       "<script src=\"https://cdn.bokeh.org/bokeh/release/bokeh-gl-3.3.4.min.js\" integrity=\"sha384-tXTWPp/bAKa+K9RPuXh7DNvye0Mv+P+6y4rAMVy+pWapsnXg9UG7g20WZ0N4i28A\" crossorigin=\"anonymous\"></script>\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "<div class=\"main\">\n",
       "    <div id=\"gsk-rag\" class=\"dark:text-white dark:bg-zinc-800 rounded border border-gray-500\">\n",
       "        <div class=\"header border-b border-b-gray-500\">\n",
       "            \n",
       "                <svg xmlns=\"http://www.w3.org/2000/svg\" width=\"60\" height=\"30\" viewBox=\"0 0 30 15\" fill=\"none\" id=\"gsk-logo\">\n",
       "                    <path fill=\"#fff\" fill-rule=\"evenodd\"\n",
       "                        d=\"M22.504 1.549a4.196 4.196 0 0 1 2.573-.887v.002a3.783 3.783 0 0 1 2.706 1.086 3.783 3.783 0 0 1 1.126 2.69 3.771 3.771 0 0 1-1.126 2.69 3.77 3.77 0 0 1-2.706 1.085l-4.794.011-2.533 3.467L8.203 15l2.881-3.335a9.829 9.829 0 0 1-4.663-1.68H3.185L0 7.163h3.934C4.263 3.165 8.187 0 12.96 0c2.24 0 4.489.696 6.175 1.909a7.423 7.423 0 0 1 1.882 1.919 4.194 4.194 0 0 1 1.487-2.28ZM7.05 3.249l3.91 3.915h1.505L7.89 2.584a7.773 7.773 0 0 0-.84.665Zm4.079-2.008 5.923 5.923h1.503l-6.086-6.087c-.45.023-.898.078-1.34.164ZM4.574 8.226h-1.77l.784.693h1.584a8.454 8.454 0 0 1-.598-.693Zm9.479 0H5.984c1.469 1.477 3.656 2.377 5.977 2.422l2.092-2.422Zm-2.458 4.472 5.492-1.902 1.878-2.569h-3.508l-3.862 4.47Zm10.361-5.552h3.265a2.714 2.714 0 0 0 1.747-4.648 2.711 2.711 0 0 0-1.888-.773 3.127 3.127 0 0 0-3.123 3.124v2.297Zm3.659-3.73a.677.677 0 1 1-.134 1.348.677.677 0 0 1 .134-1.348Z\"\n",
       "                        clip-rule=\"evenodd\" />\n",
       "                </svg>\n",
       "            <h1>RAG Evaluation Toolkit</h1>\n",
       "        </div>\n",
       "        \n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"components-container\">\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">GENERATOR</div>\n",
       "                    <div class=\"component-value tooltip  text-green \">\n",
       "                        100.0%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The Generator is the LLM inside the RAG to generate the answers.</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=100.0 class=\" progress-green \">100.0%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">RETRIEVER</div>\n",
       "                    <div class=\"component-value tooltip  text-green \">\n",
       "                        100.0%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The Retriever fetches relevant documents from the knowledge base according to a user query.</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=100.0 class=\" progress-green \">100.0%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">REWRITER</div>\n",
       "                    <div class=\"component-value tooltip  text-green \">\n",
       "                        100.0%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The Rewriter modifies the user query to match a predefined format or to include the context from the chat history.</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=100.0 class=\" progress-green \">100.0%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">ROUTING</div>\n",
       "                    <div class=\"component-value tooltip  text-green \">\n",
       "                        100.0%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The Router filters the query of the user based on his intentions (intentions detection).</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=100.0 class=\" progress-green \">100.0%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">KNOWLEDGE_BASE</div>\n",
       "                    <div class=\"component-value tooltip  text-green \">\n",
       "                        100.0%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The knowledge base is the set of documents given to the RAG to generate the answers. Its scores is computed differently from the other components: it is the difference between the maximum and minimum correctness score across all the topics of the knowledge base.</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=100.0 class=\" progress-green \">100.0%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"overall-card\">\n",
       "                    <div class=\"overall-title\">Overall Correctness Score</div>\n",
       "                    <div class=\"overall-value\">100%</div>\n",
       "                </div>\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"section-card\">\n",
       "                <div class=\"section-title\">RECOMMENDATION</div>\n",
       "                <span class=\"section-content\"> Improve the performance of the Generator for complex questions and Distracting questions, as these scores are currently not optimal. Also, ensure balanced knowledge coverage across all topics in your Knowledge Base to maintain consistency in answers.</span>\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"section-card\">\n",
       "                <div class=\"section-title\">CORRECTNESS BY TOPIC</div>\n",
       "                    <script type=\"text/javascript\">\n",
       "        (function() {\n",
       "  const fn = function() {\n",
       "    Bokeh.safely(function() {\n",
       "      (function(root) {\n",
       "        function embed_document(root) {\n",
       "        const docs_json = '{\"0022d849-5f4b-45cd-adb5-0b5d6cb8d1ed\":{\"version\":\"3.4.3\",\"title\":\"Bokeh Application\",\"roots\":[{\"type\":\"object\",\"name\":\"Figure\",\"id\":\"p1190\",\"attributes\":{\"height\":350,\"width_policy\":\"max\",\"x_range\":{\"type\":\"object\",\"name\":\"DataRange1d\",\"id\":\"p1192\",\"attributes\":{\"start\":0}},\"y_range\":{\"type\":\"object\",\"name\":\"FactorRange\",\"id\":\"p1199\",\"attributes\":{\"factors\":[\"Nitisinone Pharmacokinetics\"]}},\"x_scale\":{\"type\":\"object\",\"name\":\"LinearScale\",\"id\":\"p1200\"},\"y_scale\":{\"type\":\"object\",\"name\":\"CategoricalScale\",\"id\":\"p1201\"},\"title\":{\"type\":\"object\",\"name\":\"Title\",\"id\":\"p1197\",\"attributes\":{\"text_color\":\"#E0E0E0\",\"text_font\":\"Helvetica\",\"text_font_size\":\"14pt\"}},\"outline_line_color\":\"#E0E0E0\",\"outline_line_alpha\":0.25,\"renderers\":[{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p1219\",\"attributes\":{\"data_source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p1187\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p1188\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p1189\"},\"data\":{\"type\":\"map\",\"entries\":[[\"correctness\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"AAAAAAAAWUA=\"},\"shape\":[1],\"dtype\":\"float64\",\"order\":\"little\"}],[\"metadata_values\",[\"Nitisinone Pharmacokinetics\"]],[\"colors\",[\"#a50026\"]]]}}},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p1220\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p1221\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p1216\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"#1f77b4\"},\"fill_color\":{\"type\":\"value\",\"value\":\"#14191B\"}}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p1217\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"#1f77b4\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.1},\"fill_color\":{\"type\":\"value\",\"value\":\"#14191B\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.1},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.1}}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p1218\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"#1f77b4\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"fill_color\":{\"type\":\"value\",\"value\":\"#14191B\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}}}},{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p1228\",\"attributes\":{\"data_source\":{\"id\":\"p1187\"},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p1229\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p1230\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p1225\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"white\"},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"value\",\"value\":\"#78BBFA\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.7}}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p1226\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"white\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.1},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"value\",\"value\":\"#78BBFA\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.1},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.1}}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p1227\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"white\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"value\",\"value\":\"#78BBFA\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}}}},{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p1238\",\"attributes\":{\"visible\":false,\"data_source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p1232\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p1233\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p1234\"},\"data\":{\"type\":\"map\",\"entries\":[[\"x\",[0]],[\"y\",[0]]]}}},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p1239\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p1240\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"Line\",\"id\":\"p1235\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"line_color\":\"#EA3829\",\"line_width\":2,\"line_dash\":[6]}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"Line\",\"id\":\"p1236\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"line_color\":\"#EA3829\",\"line_alpha\":0.1,\"line_width\":2,\"line_dash\":[6]}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"Line\",\"id\":\"p1237\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"line_color\":\"#EA3829\",\"line_alpha\":0.2,\"line_width\":2,\"line_dash\":[6]}}}}],\"toolbar\":{\"type\":\"object\",\"name\":\"Toolbar\",\"id\":\"p1198\",\"attributes\":{\"tools\":[{\"type\":\"object\",\"name\":\"HoverTool\",\"id\":\"p1212\",\"attributes\":{\"renderers\":\"auto\",\"tooltips\":[[\"topic\",\"@metadata_values\"],[\"Correctness\",\"@correctness{0.00}\"]]}}]}},\"toolbar_location\":null,\"left\":[{\"type\":\"object\",\"name\":\"CategoricalAxis\",\"id\":\"p1207\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"CategoricalTicker\",\"id\":\"p1208\"},\"formatter\":{\"type\":\"object\",\"name\":\"CategoricalTickFormatter\",\"id\":\"p1209\"},\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p1210\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"below\":[{\"type\":\"object\",\"name\":\"LinearAxis\",\"id\":\"p1202\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"BasicTicker\",\"id\":\"p1203\",\"attributes\":{\"mantissas\":[1,2,5]}},\"formatter\":{\"type\":\"object\",\"name\":\"BasicTickFormatter\",\"id\":\"p1204\"},\"axis_label\":\"Correctness (%)\",\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p1205\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"center\":[{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p1206\",\"attributes\":{\"axis\":{\"id\":\"p1202\"},\"grid_line_color\":\"#E0E0E0\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p1211\",\"attributes\":{\"dimension\":1,\"axis\":{\"id\":\"p1207\"},\"grid_line_color\":\"#E0E0E0\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Span\",\"id\":\"p1231\",\"attributes\":{\"location\":100.0,\"dimension\":\"height\",\"line_color\":\"#EA3829\",\"line_width\":2,\"line_dash\":[6]}},{\"type\":\"object\",\"name\":\"Legend\",\"id\":\"p1241\",\"attributes\":{\"border_line_alpha\":0,\"background_fill_color\":\"#111516\",\"background_fill_alpha\":0.5,\"label_text_color\":\"#E0E0E0\",\"label_text_font\":\"Helvetica\",\"label_text_font_size\":\"1.025em\",\"label_standoff\":8,\"glyph_width\":15,\"spacing\":8,\"items\":[{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1242\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Correctness on the entire Testset\"},\"renderers\":[{\"id\":\"p1238\"}]}}]}}],\"background_fill_color\":\"#14191B\",\"border_fill_color\":\"#15191C\"}}]}}';\n",
       "        const render_items = [{\"docid\":\"0022d849-5f4b-45cd-adb5-0b5d6cb8d1ed\",\"roots\":{\"p1190\":\"eb2bb2c0-4f97-4be0-b47a-92611796fb07\"},\"root_ids\":[\"p1190\"]}];\n",
       "        root.Bokeh.embed.embed_items(docs_json, render_items);\n",
       "        }\n",
       "        if (root.Bokeh !== undefined) {\n",
       "          embed_document(root);\n",
       "        } else {\n",
       "          let attempts = 0;\n",
       "          const timer = setInterval(function(root) {\n",
       "            if (root.Bokeh !== undefined) {\n",
       "              clearInterval(timer);\n",
       "              embed_document(root);\n",
       "            } else {\n",
       "              attempts++;\n",
       "              if (attempts > 100) {\n",
       "                clearInterval(timer);\n",
       "                console.log(\"Bokeh: ERROR: Unable to run BokehJS code because BokehJS library is missing\");\n",
       "              }\n",
       "            }\n",
       "          }, 10, root)\n",
       "        }\n",
       "      })(window);\n",
       "    });\n",
       "  };\n",
       "  if (document.readyState != \"loading\") fn();\n",
       "  else document.addEventListener(\"DOMContentLoaded\", fn);\n",
       "})();\n",
       "    </script>\n",
       "\n",
       "                <div id=\"eb2bb2c0-4f97-4be0-b47a-92611796fb07\" data-root-id=\"p1190\" style=\"display: contents;\"></div>\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"section-card\">\n",
       "                <div class=\"section-title\">KNOWLEDGE BASE OVERVIEW</div>\n",
       "                    <script type=\"text/javascript\">\n",
       "        (function() {\n",
       "  const fn = function() {\n",
       "    Bokeh.safely(function() {\n",
       "      (function(root) {\n",
       "        function embed_document(root) {\n",
       "        const docs_json = '{\"76e4be16-ba0e-4137-b0be-f2985b04dc0d\":{\"version\":\"3.4.3\",\"title\":\"Bokeh Application\",\"roots\":[{\"type\":\"object\",\"name\":\"Tabs\",\"id\":\"p1121\",\"attributes\":{\"sizing_mode\":\"stretch_width\",\"tabs\":[{\"type\":\"object\",\"name\":\"TabPanel\",\"id\":\"p1052\",\"attributes\":{\"title\":\"Topic exploration\",\"child\":{\"type\":\"object\",\"name\":\"Figure\",\"id\":\"p1004\",\"attributes\":{\"sizing_mode\":\"stretch_width\",\"x_range\":{\"type\":\"object\",\"name\":\"Range1d\",\"id\":\"p1013\",\"attributes\":{\"start\":6.380357480049133,\"end\":14.755448627471925}},\"y_range\":{\"type\":\"object\",\"name\":\"Range1d\",\"id\":\"p1014\",\"attributes\":{\"start\":-2.8237056732177734,\"end\":5.5318111181259155}},\"x_scale\":{\"type\":\"object\",\"name\":\"LinearScale\",\"id\":\"p1015\"},\"y_scale\":{\"type\":\"object\",\"name\":\"LinearScale\",\"id\":\"p1016\"},\"title\":{\"type\":\"object\",\"name\":\"Title\",\"id\":\"p1011\",\"attributes\":{\"text_color\":\"#E0E0E0\",\"text_font\":\"Helvetica\",\"text_font_size\":\"14pt\"}},\"outline_line_color\":\"#E0E0E0\",\"outline_line_alpha\":0.25,\"renderers\":[{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p1044\",\"attributes\":{\"data_source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p1001\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p1002\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p1003\"},\"data\":{\"type\":\"map\",\"entries\":[[\"x\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"m7omQdYJF0FcnxNBl2QEQTQUBUHl3h5Bq/c6QXkdEEG5KQxBW4QSQacWGkGPJyBBFxUpQTb+HEEn+SdBDzz/QEwJ60CWSfFA8UrUQBAR6UCDhgBBFdUiQYa3GEFGfh9BTWYLQa/LMEEAXDtBt48yQbMqHEG+uwtB43QRQcAM8EBZcwJBwvjgQHaeLEE/ezVBgk0vQQnoJUFGvRRBTgkMQcM7IEEzjgRBgK0OQZy6GkEUKhNB9+YOQQ==\"},\"shape\":[46],\"dtype\":\"float32\",\"order\":\"little\"}],[\"y\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"EVckQGNbzj+732q/18+vv0Pj477qBLY/DtOKP0jSpr7kKfc/yQaQPoG9ML+pgsW+az4xPu0ut7+LTpO/TaQBPdB5Jr/pI94/QTKvP/GfqD/aQaE/YsV9P3EiOj44ZhxAE+4yQFjAsj9/TJc+SGg5PykkUz937KQ/rppoP9qhUT4U/tk+wFxAP9EG7j7Pg5i+KZMtv+nb+T8few9A/3ahv12iTUDuRVpA4I9JQPdoZ0Bx62hAiHSEQA==\"},\"shape\":[46],\"dtype\":\"float32\",\"order\":\"little\"}],[\"topic\",[\"Nitisinone Pharmacokinetics\",\"Nitisinone Pharmacokinetics\",\"Nitisinone Pharmacokinetics\",\"Others\",\"Nitisinone Pharmacokinetics\",\"Nitisinone Pharmacokinetics\",\"Nitisinone Treatment for HT-1\",\"Nitisinone Pharmacokinetics\",\"Nitisinone Pharmacokinetics\",\"Nitisinone Pharmacokinetics\",\"Nitisinone Pharmacokinetics\",\"Nitisinone Pharmacokinetics\",\"Others\",\"Others\",\"Nitisinone Treatment for HT-1\",\"Nitisinone Pharmacokinetics\",\"Others\",\"Nitisinone Pharmacokinetics\",\"Nitisinone Pharmacokinetics\",\"Nitisinone Pharmacokinetics\",\"Nitisinone Pharmacokinetics\",\"Nitisinone Pharmacokinetics\",\"Nitisinone Pharmacokinetics\",\"Nitisinone Pharmacokinetics\",\"Nitisinone Capsules\",\"Nitisinone Treatment for HT-1\",\"Nitisinone Treatment for HT-1\",\"Nitisinone Treatment for HT-1\",\"Nitisinone Pharmacokinetics\",\"Nitisinone Pharmacokinetics\",\"Nitisinone Pharmacokinetics\",\"Nitisinone Pharmacokinetics\",\"Nitisinone Pharmacokinetics\",\"Nitisinone Pharmacokinetics\",\"Nitisinone Treatment for HT-1\",\"Nitisinone Treatment for HT-1\",\"Nitisinone Treatment for HT-1\",\"Nitisinone Pharmacokinetics\",\"Nitisinone Pharmacokinetics\",\"Nitisinone Pharmacokinetics\",\"Nitisinone Capsules\",\"Nitisinone Capsules\",\"Nitisinone Capsules\",\"Nitisinone Capsules\",\"Nitisinone Capsules\",\"Others\"]],[\"id\",[0,1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45]],[\"content\",[\"NITISINONE- nitisinone capsule Analog Pharma\\\\n\\\\n----------\\\\n\\\\nHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use NITISINONE CAPSULES safely and effectively. See full prescribing information for NITISINONE CAPSULES.\\\\n\\\\nNITISINONE capsules, for oral use Initial U.S. Approval: 2002\\\\n\\\\nINDICATIONS AND USAGE\\\\n\\\\nNitisinone capsules are a hydroxy-phenylpyruvate dioxygenase inhibitor indicated for the treatment of adult and pediatric patients with hereditary ty...\",\"The recommended starting dosage is 0.5 mg/kg orally twice daily. In patients 5 years of age and older who have undetectable serum and urine succinylacetone concentrations after a minimum of 4 weeks on a stable dosage of nitisinone, the total daily dose may be given once daily. Titrate the dosage based on biochemical and/or clinical response, as described in the full prescribing information. The maximum total daily dosage is 2 mg/kg orally.\\\\n\\\\nAdministration (2.2):\\\\n\\\\nMaintain dietary restriction of ...\",\"Elevated Plasma Tyrosine Levels, Ocular Symptoms, Developmental Delay and Hyperkeratotic Plaques: Inadequate restriction of tyrosine and phenylalanine intake can lead to elevations in plasma tyrosine, which at levels above 500 micromol/L can result in symptoms, intellectual disability and developmental delay or painful hyperkeratotic plaques on the soles and palms; do not adjust nitisinone capsules dosage in order to lower the plasma tyrosine concentration. Obtain slit-lamp examination prior to ...\",\"ADVERSE REACTIONS\\\\n\\\\nMost common adverse reactions (&gt;1%) are elevated tyrosine levels, thrombocytopenia, leukopenia, conjunctivitis, corneal opacity, keratitis, photophobia, eye pain, blepharitis, cataracts, granulocytopenia, epistaxis, pruritus, exfoliative dermatitis, dry skin, maculopapular rash and alopecia. (6.1)\\\\n\\\\nTo report SUSPECTED ADVERSE REACTIONS, contact Analog Pharma Inc. at 1-844-884-5505 or medicalinfo@analogpharma.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. DRUG INTERACTIO...\",\"Revised: 6/2023\\\\n\\\\nFULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION\\\\n\\\\n2.1 Dosage 2.2 Administration\\\\n\\\\n3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS\\\\n\\\\n5.1 Elevated Plasma Tyrosine Levels, Ocular Symptoms, Developmental Delay and Hyperkeratotic Plaques 5.2 Leukopenia and Severe Thrombocytopenia\\\\n\\\\n6 ADVERSE REACTIONS\\\\n\\\\n6.1 Clinical Trials Experience\\\\n\\\\n7 DRUG INTERACTIONS 8 USE IN SPECIFIC POPULATIONS\\\\n\\\\n8.1 Pregnancy 8.2 Lactation 8.4 P...\",\"Nitisinone capsules are indicated for the treatment of adult and pediatric patients with hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine.\\\\n\\\\n2 DOSAGE AND ADMINISTRATION\\\\n\\\\n2.1 Dosage\\\\n\\\\nStarting Dosage\\\\n\\\\nThe recommended starting dosage of nitisinone capsules is 0.5 mg/kg administered orally twice daily.\\\\n\\\\nMaintenance Regimen\\\\n\\\\nIn patients 5 years of age and older who have undetectable serum and urine succinylacetone concentrations after a minimum...\",\"Monitor plasma and/or urine succinylacetone concentrations, liver function parameters and alpha-fetoprotein levels. If succinylacetone is still detectable in blood or urine 4 weeks after the start of nitisinone treatment, increase the nitisinone dosage to 0.75 mg/kg twice daily. A maximum total daily dosage of 2 mg/kg may be needed based on the evaluation of all biochemical parameters. If the biochemical response is satisfactory (undetectable blood and/or urine succinylacetone), the dosage shoul...\",\"levels below 500 micromol/L by dietary restriction of tyrosine and phenylalanine intake [see Warnings and Precautions (5.1)]. In patients who develop plasma tyrosine levels above 500 micromol/L, assess dietary tyrosine and phenylalanine intake. Do not adjust the nitisinone capsules dosage in order to lower the plasma tyrosine concentration.\",\"2.2 Administration\\\\n\\\\nAdministration of Nitisinone Capsules\\\\n\\\\nMaintain dietary restriction of tyrosine and phenylalanine when taking nitisinone capsules. Take at least one hour before, or two hours after a meal [see Clinical Pharmacology (12.3)]. For patients who have difficulty swallowing the capsules, the capsules may be opened and the contents suspended in a small amount of water, formula or apple sauce immediately before use.\\\\n\\\\n3 DOSAGE FORMS AND STRENGTHS\\\\n\\\\nCapsules: 2 mg, 5 mg, 10 mg and 20 mg ...\",\"Nitisinone is an inhibitor of 4-hydroxyphenyl-pyruvate dioxygenase, an enzyme in the tyrosine metabolic pathway [see Clinical Pharmacology (12.1)]. Therefore, treatment with nitisinone capsules may cause an increase in plasma tyrosine levels in patients with HT-1. Maintain concomitant reduction in dietary tyrosine and phenylalanine while on nitisinone capsules treatment. Do not adjust nitisinone capsules dosage in order to lower the plasma tyrosine concentration. Maintain plasma tyrosine levels ...\",\"restriction and reported tyrosine levels &gt;500 micromol/L both symptomatic and asymptomatic keratopathies have been observed. Therefore, perform a baseline ophthalmologic examination including slit-lamp examination prior to initiating nitisinone capsules treatment and regularly thereafter. Patients who develop photophobia, eye pain, or signs of inflammation such as redness, swelling, or burning of the eyes or tyrosine levels are &gt; 500 micromol/L during treatment with nitisinone capsules should un...\",\"In patients with HT-1 treated with dietary restrictions and nitisinone capsules who develop elevated plasma tyrosine levels, assess dietary tyrosine and phenylalanine intake.\\\\n\\\\n5.2 Leukopenia and Severe Thrombocytopenia\\\\n\\\\nIn clinical trials, patients treated with nitisinone and dietary restriction developed transient leukopenia (3%), thrombocytopenia (3%), or both (1.5%) [see Adverse Reactions (6.1)]. No patients developed infections or bleeding as a result of the episodes of leukopenia and thromb...\",\"Nitisinone was studied in one open-label, uncontrolled study of 207 patients with HT-1, ages 0 to 22 years at enrollment (median age 9 months), who were diagnosed with HT-1 by the presence of succinylacetone in the urine or plasma. The starting dose of nitisinone was 0.3 to 0.5 mg/kg twice daily, and the dose was increased in some patients to 1 mg/kg twice daily based on weight, biochemical, and enzyme markers. The recommended starting dosage of nitisinone is 0.5 mg/kg twice daily [see Dosage an...\",\"The most serious adverse reactions reported during nitisinone treatment were thrombocytopenia, leukopenia, porphyria, and ocular/visual complaints associated with elevated tyrosine levels [see Warnings and Precautions (5.1, 5.2)]. Fourteen patients experienced ocular/visual events. The duration of the symptoms varied from 5 days to 2 years. Six patients had thrombocytopenia, three of which had platelet counts 30,000/microL or lower. In 4 patients with thrombocytopenia, platelet counts gradually ...\",\"Patients with HT-1 are at increased risk of developing porphyric crises, hepatic neoplasms, and liver failure requiring liver transplantation. These complications of HT-1 were observed in patients treated with nitisinone for a median of 22 months during the clinical trial (liver transplantation 13%, liver failure 7%, malignant hepatic neoplasms 5%, benign hepatic neoplasms 3%, porphyria 1%).\\\\n\\\\nThe most common adverse reactions reported in the clinical trial are summarized in Table 1.\\\\n\\\\nTABLE 1 Mos...\",\"Adverse reactions reported in less than 1% of the patients, included death, seizure, brain tumor, encephalopathy, hyperkinesia, cyanosis, abdominal pain, diarrhea, enanthema, gastrointestinal hemorrhage, melena, elevated hepatic enzymes, liver enlargement, hypoglycemia, septicemia, and bronchitis.\\\\n\\\\n7 DRUG INTERACTIONS\\\\n\\\\nNitisinone is a moderate CYP2C9 inhibitor, a weak CYP2E1 inducer and an inhibitor of OAT1/OAT3. Table 2 includes drugs with clinically important drug interactions when administere...\",\"Intervention\\\\n\\\\nIncreased exposure of the co-administered drugs metabolized by CYP2C9. [see Clinical Pharmacology (12.3)] Reduce the dosage of the co-administered drugs metabolized by CYP2C9 drug by half. Additional dosage adjustment may be needed to maintain therapeutic drug concentrations for narrow therapeutic index drugs. See prescribing information for those drugs.\\\\n\\\\nOAT1/OAT3 Substrates (e.g., adefovir, ganciclovir, methotrexate)\\\\n\\\\nClinical Impact\\\\n\\\\nIntervention\\\\n\\\\nIncreased exposure of the inter...\",\"Risk Summary\\\\n\\\\nLimited available data with nitisinone use in pregnant women are not sufficient to determine a drug-associated risk of adverse developmental outcomes. Animal reproduction studies have been conducted for nitisinone. In these studies, nitisinone was administered to mice and rabbits during organogenesis with oral doses of nitisinone up to 20 and 8 times respectively, the recommended initial dose of 1 mg/kg/day. In mice, nitisinone caused incomplete skeletal ossification of fetal bones...\",\"The background risk of major birth defects and miscarriage for the indicated population are unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.\\\\n\\\\nData\\\\n\\\\nAnimal Data\",\"Data\\\\n\\\\nAnimal Data\\\\n\\\\nReproduction studies have been performed in mice at oral doses of about 0.4, 4 and 20 times the recommended initial dose (1 mg/kg/day) and in rabbits at oral doses of about 1.6, 4 and 8 times the recommended initial dose based on the body surface area. In mice, nitisinone has been shown to cause incomplete skeletal ossification of fetal bones at 0.4, 4 and 20 times the recommended initial dose, increased gestational length at 4 and 20 times the recommended initial dose, and de...\",\"Risk Summary\\\\n\\\\nThere are no data on the presence of nitisinone in human milk, the effects on the breastfed infant, or the effects on milk production. Data suggest that nitisinone is present in rat milk due to findings of ocular toxicity and lower body weight seen in drug naive nursing rat pups. The development and health benefits of breastfeeding should be considered along with the mother\\\\u2019s clinical need for nitisinone capsules and any potential adverse effects on the breastfed infant from nitisi...\",\"8.5 Geriatric Use\\\\n\\\\nClinical studies of nitisinone did not include any subjects aged 65 and over. No pharmacokinetic studies of nitisinone have been performed in geriatric patients. In general, dose selection for an elderly patient should be cautious reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and concomitant disease or other drug therapy in this patient population.\\\\n\\\\n10 OVERDOSAGE\",\"10 OVERDOSAGE\\\\n\\\\nAccidental ingestion of nitisinone capsules by individuals eating normal diets not restricted in tyrosine and phenylalanine will result in elevated tyrosine levels. In healthy subjects given a single 1 mg/kg dose of nitisinone, the plasma tyrosine level reached a maximum of 1200 micromol/L at 48 to 120 hours after dosing. After a washout period of 14 days, the mean value of plasma tyrosine was still 808 micromol/L. Fasted follow-up samples obtained from volunteers several weeks la...\",\"11 DESCRIPTION\\\\n\\\\nNitisinone capsules contain nitisinone, which is a hydroxyphenyl-pyruvate dioxygenase inhibitor indicated as an adjunct to dietary restriction of tyrosine and phenylalanine in the treatment of hereditary tyrosinemia type 1 (HT-1).\\\\n\\\\nNitisinone occurs as white to yellowish-white, crystalline powder. It is practically insoluble in water, soluble in 2M sodium hydroxide and in methanol, and sparingly soluble in alcohol.\\\\n\\\\nChemically, nitisinone is 2-(2-nitro-4-trifluoromethylbenzoyl) c...\",\"logo on the capsule cap: nitisinone, plus pre-gelatinized starch and stearic acid. The capsule shell is gelatin and titanium dioxide and the blue imprint is composed of FD &amp; C Blue #2-Aluminum Lake, shellac, propylene glycol and strong ammonia solution.\\\\n\\\\n. Each capsule contains 2 mg, 5 mg, 10 mg or 20 mg\\\\n\\\\n12 CLINICAL PHARMACOLOGY\\\\n\\\\n12.1 Mechanism of Action\",\"Nitisinone is a competitive inhibitor of 4-hydroxyphenyl-pyruvate dioxygenase, an enzyme upstream of fumarylacetoacetate hydrolase (FAH) in the tyrosine catabolic pathway. By inhibiting the normal catabolism of tyrosine in patients with HT-1, nitisinone prevents the accumulation of the catabolic intermediates maleylacetoacetate and fumarylacetoacetate. In patients with HT-1, these catabolic intermediates are converted to the toxic metabolites succinylacetone and succinylacetoacetate, which are r...\",\"In a clinical study, patients with HT-1 were diagnosed by the presence of succinylacetone in urine or plasma and treated with nitisinone [see Clinical Studies (14)]. In all 186 patients whose urine succinylacetone was measured, the urinary succinylacetone concentration decreased to less than 1 mmol/mol creatinine, the lower limit of quantitation. The median time to normalization of urine succinylacetone was 0.3 months. The probability of recurrence of abnormal values of urine succinylacetone was...\",\"In another study, comparing two dosing regimens, succinylacetone was measured in urine and/or blood in 16 patients with HT-1 aged 5 years to 24 years. All study patients were on a stable nitisinone daily dosage (0.4 mg/kg/day to 1 mg/kg/day) during both study dosing regimens. After at least 4 weeks of twice daily dosing with nitisinone, both the urine and/or blood succinylacetone concentrations were below the limit of quantitation for the assay. Patients were then switched to once daily dosing w...\",\"Nitisinone inhibits catabolism of the amino acid tyrosine and can result in elevated plasma levels of tyrosine. Therefore, treatment with nitisinone requires restriction of the dietary intake of tyrosine and phenylalanine to prevent the toxicity associated with elevated plasma levels of tyrosine [see Warnings and Precautions (5.1)].\\\\n\\\\n12.3 Pharmacokinetics\\\\n\\\\nThe single-dose pharmacokinetics of nitisinone have been studied in healthy adult subjects and the multiple-dose pharmacokinetics have been s...\",\"TABLE 3\\\\n\\\\nNitisinone Arithmetic Mean (CV%) Pharmacokinetic Parameters in Healthy Subjects Following a Single Oral 30 mg Dose of Nitisinone Under Fasting Conditions\\\\n\\\\nTreatment\\\\n\\\\nNitisinone capsules (n=12)\\\\n\\\\nC (micromol/L) [range]\\\\n\\\\nmax\\\\n\\\\n10.5 (26)\\\\n\\\\nt max (h) [range] 3.5 [0.8 to 8.0]\\\\n\\\\n\\\\n\\\\nAUC (micromol\\\\u00b7h/L) [range]\\\\n\\\\n0-72h\\\\n\\\\n406 (13)\\\\n\\\\npresented as median [range]\\\\n\\\\nTABLE 4\\\\n\\\\nNitisinone Arithmetic Mean (CV%) Pharmacokinetic Parameters in Healthy Subjects Following Repeated Once Daily Administration of 80 mg Ni...\",\"Distribution\\\\n\\\\nIn vitro binding of nitisinone to human plasma proteins is greater than 95% at 50 micromolar concentration.\\\\n\\\\nElimination\\\\n\\\\nThe mean terminal plasma half-life of single dose nitisinone in healthy male subjects is 54 hours. The mean (CV%) apparent plasma clearance in 18 healthy adults following multiple once daily doses of nitisinone 80 mg is 113 (16) mL/h.\\\\n\\\\nMetabolism: In vitro studies have shown that nitisinone is relatively stable in human liver microsomes with minor metabolism pos...\",\"Nitisinone does not inhibit CYP2D6. Nitisinone is a moderate inhibitor of CYP2C9, and a weak inducer of CYP2E1 (Table 5). Nitisinone is an inhibitor of OAT1/3 (Table 5).\\\\n\\\\nTABLE 5.\\\\n\\\\nPercent change in AUC Presence of Nitisinone in 18 Healthy Subjects\\\\n\\\\nand C\\\\n\\\\nfor Co-administered Drugs in the\\\\n\\\\n0-\\\\u221e\\\\n\\\\nmax\\\\n\\\\nCo- administered a drug\\\\n\\\\nDose of Co- administered Drug (Route of Administration)\\\\n\\\\nEffect of Nitisinone on the Pharmacokinetics of Co- administered Drug AUC\\\\n\\\\nb\\\\n\\\\nC\\\\n\\\\n0-\\\\u221e\\\\n\\\\nmax\\\\n\\\\nCYP2C9 Substrate c Tolbuta...\",\"In vitro Studies Where Drug Interaction Potential Was Not Evaluated Clinically\\\\n\\\\nIn vitro studies showed that nitisinone does not inhibit CYP1A2, 2C19, or 3A4. Nitisinone does not induce CYP1A2, 2B6 or 3A4/5. Nitisinone does not inhibit P-gp, BCRP, OATP1B1, OATP1B3 and OCT2-mediated transports at therapeutically relevant concentrations.\\\\n\\\\n13 NONCLINICAL TOXICOLOGY\\\\n\\\\n13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility\\\\n\\\\nThe carcinogenic potential of nitisinone was assessed in a 26-week oral (ga...\",\"+/-\\\\n\\\\n) forward mutation test and in an in vivo mouse bone marrow\\\\n\\\\nIn a single dose-group study in rats given 100 mg/kg (16.2 times the recommended initial dose of 1 mg/kg/day on a body surface area basis), reduced litter size, decreased pup weight at birth, and decreased survival of pups after birth was demonstrated.\\\\n\\\\n14 CLINICAL STUDIES\",\"The efficacy and safety of nitisinone in patients with HT-1 was evaluated in one open- label, uncontrolled study of 207 patients with HT-1, ages 0 to 22 years at enrollment (median age 9 months). Patients were diagnosed with HT-1 by the presence of succinylacetone in the urine or plasma. All patients were treated with nitisinone at a starting dose of 0.3 to 0.5 mg/kg twice daily, and the dose was increased in some patients to 1 mg/kg twice daily based on weight, liver and kidney function tests, ...\",\"For patients presenting with HT-1 younger than 2 months of age who were treated with dietary restriction and nitisinone, 2- and 4-year survival probabilities were 88% and 88%, respectively. Data from historical controls showed that patients presenting with HT-1 at younger than 2 months of age and treated with dietary restriction alone had 2- and 4- year survival probabilities of 29% and 29%, respectively. For patients presenting with HT-1 between 2 months and 6 months of age who were treated wit...\",\"Porphyria-like crisis were reported in 3 patients (0.3% of cases per year) during the clinical study. This compares to an incidence of 5 to 20% of cases per year expected as part of the natural history of the disorder. An assessment of porphyria-like crises was performed because these events are commonly reported in patients with HT-1 who are not treated with nitisinone.\\\\n\\\\nUrinary alpha-1-microglobulin, a proposed marker of proximal tubular dysfunction, was measured in 100 patients at baseline. T...\",\"alpha-1-microglobulin levels decreased from 5.0 to 3.0 grams/mol creatinine (reference value for age less than or equal to 12 grams/mol creatinine). In patients older than 24 months in whom multiple values were available (N=35), median alpha-1-microglobulin levels decreased from 2.8 to 2.0 grams/mol creatinine (reference for age less than or equal to 6 grams/mol creatinine).\\\\n\\\\nThe long-term effect of nitisinone on hepatic function was not assessed.\\\\n\\\\n16 HOW SUPPLIED/STORAGE AND HANDLING\\\\n\\\\nWhite cap...\",\"5 mg white capsules imprinted with the following logo on the capsule cap: on the capsule body in blue ink, NDC 70505-205-60\\\\n\\\\n10 mg white capsules imprinted with the following logo on the capsule cap: \\\\u201c10\\\\u201d on the capsule body in blue ink, NDC 70505-210-60\\\\n\\\\n20 mg white capsules imprinted with the following logo on the capsule cap: \\\\u201c20\\\\u201d on the capsule body in blue ink, NDC 70505-220-60\\\\n\\\\nStore at 25\\\\u00baC (77\\\\u00baF); excursions permitted to 15\\\\u00ba\\\\u201330\\\\u00baC (59\\\\u00ba - 86\\\\u00baF) [see USP Controlled Room Temperature]\\\\n\\\\n17 PAT...\",\"Elevated Plasma Tyrosine Levels, Ocular Symptoms, Developmental Delay and Hyperkeratotic Plaques\\\\n\\\\nInform patients that inadequate restriction may be associated with ocular signs and\\\\n\\\\n, and\\\\n\\\\n, and \\\\u201c2\\\\u201d\\\\n\\\\n, and \\\\u201c5\\\\u201d\\\\n\\\\n, and\\\\n\\\\n, and\\\\n\\\\nsymptoms, intellectual disability and developmental delay, and painful hyperkeratotic plaques on the soles and palms. Advise patients and caregivers of the need to maintain dietary restriction of tyrosine and phenylalanine and to report any unexplained ocular, neurologic, o...\",\"NDC 70505-205-60 Nitisinone Capsules 5 mg\\\\n\\\\n60 capsules\\\\n\\\\nPRINCIPAL DISPLAY PANEL - 5 mg Carton\\\\n\\\\nNDC 70505-205-60 Nitisinone Capsules 5 mg\\\\n\\\\nFor Oral Use\\\\n\\\\nANALOG PHARMA\\\\n\\\\n60 capsules\\\\n\\\\nPRINCIPAL DISPLAY PANEL - 10 mg Container\\\\n\\\\nNDC 70505-210-60 Nitisinone Capsules 10 mg\\\\n\\\\n60 capsules\\\\n\\\\nPRINCIPAL DISPLAY PANEL - 10 mg Carton\\\\n\\\\nNDC 70505-210-60 Nitisinone Capsules 10 mg\\\\n\\\\nFor Oral Use\\\\n\\\\nANALOG PHARMA\\\\n\\\\n60 capsules\\\\n\\\\nPRINCIPAL DISPLAY PANEL - 20 mg Container\\\\n\\\\nNDC 70505-220-60 Nitisinone Capsules 20 mg\\\\n\\\\n60 caps...\",\"Ingredient Name\\\\n\\\\nMODIFIED CORN STARCH (1-OCTENYL SUCCINIC ANHYDRIDE) (UNII: 461P5CJN6T)\\\\n\\\\nGELATIN, UNSPECIFIED (UNII: 2G86QN327L)\\\\n\\\\nSTEARIC ACID (UNII: 4ELV7Z65AP)\\\\n\\\\nTITANIUM DIOXIDE (UNII: 15FIX9V2JP)\\\\n\\\\nFD&amp;C BLUE NO. 2--ALUMINUM LAKE (UNII: 4AQJ3LG584)\\\\n\\\\nSHELLAC (UNII: 46N107B71O)\\\\n\\\\nPROPYLENE GLYCOL (UNII: 6DC9Q167V3)\\\\n\\\\nAMMONIA (UNII: 5138Q19F1X)\\\\n\\\\nNDC:70505-202\\\\n\\\\nStrength\\\\n\\\\n2 mg\\\\n\\\\nStrength\\\\n\\\\nProduct Characteristics\\\\n\\\\nColor\\\\n\\\\nwhite\\\\n\\\\nScore\\\\n\\\\nno score\\\\n\\\\nShape\\\\n\\\\nCAPSULE\\\\n\\\\nSize\\\\n\\\\n16mm\\\\n\\\\nFlavor\\\\n\\\\nImprint Code\\\\n\\\\n2;logo\\\\n\\\\nC...\",\"NDC:70505-205\\\\n\\\\nRoute of Administration\\\\n\\\\nORAL\\\\n\\\\nActive Ingredient/Active Moiety\\\\n\\\\nIngredient Name\\\\n\\\\nBasis of Strength\\\\n\\\\nStrength\\\\n\\\\nNITISINONE (UNII: K5BN214699) (NITISINONE - UNII:K5BN214699)\\\\n\\\\nNITISINONE\\\\n\\\\n5 mg\\\\n\\\\nInactive Ingredients\\\\n\\\\nIngredient Name\\\\n\\\\nStrength\\\\n\\\\nMODIFIED CORN STARCH (1-OCTENYL SUCCINIC ANHYDRIDE) (UNII: 461P5CJN6T)\\\\n\\\\nGELATIN, UNSPECIFIED (UNII: 2G86QN327L)\\\\n\\\\nSTEARIC ACID (UNII: 4ELV7Z65AP)\\\\n\\\\nTITANIUM DIOXIDE (UNII: 15FIX9V2JP)\\\\n\\\\nFD&amp;C BLUE NO. 2--ALUMINUM LAKE (UNII: 4AQJ3LG584)\\\\n\\\\nSHELLAC (UNI...\",\"Marketing Start Date\\\\n\\\\nMarketing End Date\\\\n\\\\nANDA\\\\n\\\\nANDA212390\\\\n\\\\n06/15/2022\\\\n\\\\nNITISINONE nitisinone capsule\\\\n\\\\nProduct Information\\\\n\\\\nProduct Type\\\\n\\\\nHUMAN PRESCRIPTION DRUG\\\\n\\\\nItem Code (Source)\\\\n\\\\nNDC:70505-210\\\\n\\\\nRoute of Administration\\\\n\\\\nORAL\\\\n\\\\nActive Ingredient/Active Moiety\\\\n\\\\nIngredient Name\\\\n\\\\nBasis of Strength\\\\n\\\\nStrength\\\\n\\\\nNITISINONE (UNII: K5BN214699) (NITISINONE - UNII:K5BN214699)\\\\n\\\\nNITISINONE\\\\n\\\\n10 mg\\\\n\\\\nInactive Ingredients\\\\n\\\\nIngredient Name\\\\n\\\\nStrength\\\\n\\\\nMODIFIED CORN STARCH (1-OCTENYL SUCCINIC ANHYDRIDE) (UNII: 461...\",\"NDC:70505- 210-60\\\\n\\\\n1 in 1 CARTON\\\\n\\\\n06/15/2022\\\\n\\\\n1\\\\n\\\\n60 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product\\\\n\\\\nMarketing Information\\\\n\\\\nMarketing Category\\\\n\\\\nApplication Number or Monograph Citation\\\\n\\\\nMarketing Start Date\\\\n\\\\nMarketing End Date\\\\n\\\\nANDA\\\\n\\\\nANDA212390\\\\n\\\\n06/15/2022\\\\n\\\\nNITISINONE nitisinone capsule\\\\n\\\\nProduct Information\\\\n\\\\nProduct Type\\\\n\\\\nHUMAN PRESCRIPTION DRUG\\\\n\\\\nItem Code (Source)\\\\n\\\\nNDC:70505-220\\\\n\\\\nRoute of Administration\\\\n\\\\nORAL\\\\n\\\\nActive Ingredient/Active Moiety\\\\n\\\\nIngredient Name\\\\n\\\\nBasis of Strength\\\\n\\\\nStrength...\",\"Color\\\\n\\\\nwhite\\\\n\\\\nScore\\\\n\\\\nShape\\\\n\\\\nCAPSULE\\\\n\\\\nSize\\\\n\\\\nFlavor\\\\n\\\\nImprint Code\\\\n\\\\nContains\\\\n\\\\nPackaging\\\\n\\\\n# Item Code\\\\n\\\\nPackage Description\\\\n\\\\n1\\\\n\\\\nNDC:70505- 220-60\\\\n\\\\n1 in 1 CARTON\\\\n\\\\n1\\\\n\\\\n60 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product\\\\n\\\\nMarketing Information\\\\n\\\\nMarketing Category\\\\n\\\\nApplication Number or Monograph Citation\\\\n\\\\nANDA\\\\n\\\\nANDA212390\\\\n\\\\nLabeler - Analog Pharma (080132990)\\\\n\\\\nRevised: 12/2024\\\\n\\\\nMarketing Start Date\\\\n\\\\n05/08/2023\\\\n\\\\nMarketing Start Date\\\\n\\\\n05/08/2023\\\\n\\\\nno score\\\\n\\\\n18mm\\\\n\\\\n20;logo\\\\n\\\\nMarketing End Date\\\\n\\\\nMarketing...\"]],[\"color\",{\"type\":\"ndarray\",\"array\":[\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#999\",\"#aec7e8\",\"#aec7e8\",\"#1f77b4\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#999\",\"#999\",\"#1f77b4\",\"#aec7e8\",\"#999\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#ff7f0e\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#999\"],\"shape\":[46],\"dtype\":\"object\",\"order\":\"little\"}]]}}},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p1045\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p1046\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1041\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.7},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.7}}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1042\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.1},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.1},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.1}}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1043\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}}}}],\"toolbar\":{\"type\":\"object\",\"name\":\"Toolbar\",\"id\":\"p1012\",\"attributes\":{\"logo\":\"grey\",\"tools\":[{\"type\":\"object\",\"name\":\"HoverTool\",\"id\":\"p1027\",\"attributes\":{\"renderers\":\"auto\",\"tooltips\":\"\\\\n    &lt;div style=\\\\\"width:400px;\\\\\"&gt;\\\\n    &lt;b&gt;Document id:&lt;/b&gt; @id &lt;br&gt;\\\\n    &lt;b&gt;Topic:&lt;/b&gt; @topic &lt;br&gt;\\\\n    &lt;b&gt;Document Content:&lt;/b&gt; @content\\\\n    &lt;/div&gt;\\\\n    \"}},{\"type\":\"object\",\"name\":\"PanTool\",\"id\":\"p1028\"},{\"type\":\"object\",\"name\":\"WheelZoomTool\",\"id\":\"p1029\",\"attributes\":{\"renderers\":\"auto\"}},{\"type\":\"object\",\"name\":\"BoxZoomTool\",\"id\":\"p1030\",\"attributes\":{\"overlay\":{\"type\":\"object\",\"name\":\"BoxAnnotation\",\"id\":\"p1031\",\"attributes\":{\"syncable\":false,\"level\":\"overlay\",\"visible\":false,\"left\":{\"type\":\"number\",\"value\":\"nan\"},\"right\":{\"type\":\"number\",\"value\":\"nan\"},\"top\":{\"type\":\"number\",\"value\":\"nan\"},\"bottom\":{\"type\":\"number\",\"value\":\"nan\"},\"left_units\":\"canvas\",\"right_units\":\"canvas\",\"top_units\":\"canvas\",\"bottom_units\":\"canvas\",\"line_color\":\"black\",\"line_alpha\":1.0,\"line_width\":2,\"line_dash\":[4,4],\"fill_color\":\"lightgrey\",\"fill_alpha\":0.5}}}},{\"type\":\"object\",\"name\":\"ResetTool\",\"id\":\"p1036\"},{\"type\":\"object\",\"name\":\"SaveTool\",\"id\":\"p1037\"}]}},\"left\":[{\"type\":\"object\",\"name\":\"LinearAxis\",\"id\":\"p1022\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"BasicTicker\",\"id\":\"p1023\",\"attributes\":{\"mantissas\":[1,2,5]}},\"formatter\":{\"type\":\"object\",\"name\":\"BasicTickFormatter\",\"id\":\"p1024\"},\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p1025\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"below\":[{\"type\":\"object\",\"name\":\"LinearAxis\",\"id\":\"p1017\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"BasicTicker\",\"id\":\"p1018\",\"attributes\":{\"mantissas\":[1,2,5]}},\"formatter\":{\"type\":\"object\",\"name\":\"BasicTickFormatter\",\"id\":\"p1019\"},\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p1020\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"center\":[{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p1021\",\"attributes\":{\"axis\":{\"id\":\"p1017\"},\"grid_line_color\":\"white\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p1026\",\"attributes\":{\"dimension\":1,\"axis\":{\"id\":\"p1022\"},\"grid_line_color\":\"white\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Legend\",\"id\":\"p1047\",\"attributes\":{\"title\":\"Knowledge Base Tospics\",\"title_text_color\":\"#B1B1B1\",\"title_text_font_style\":\"bold\",\"border_line_alpha\":0,\"background_fill_color\":\"#111516\",\"background_fill_alpha\":0.5,\"label_text_color\":\"#E0E0E0\",\"label_text_font\":\"Helvetica\",\"label_text_font_size\":\"1.025em\",\"label_standoff\":8,\"glyph_width\":15,\"spacing\":8,\"items\":[{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1048\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Nitisinone Capsules\"},\"renderers\":[{\"id\":\"p1044\"}],\"index\":24}},{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1049\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Nitisinone Pharmacokinetics\"},\"renderers\":[{\"id\":\"p1044\"}],\"index\":0}},{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1050\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Nitisinone Treatment for HT-1\"},\"renderers\":[{\"id\":\"p1044\"}],\"index\":6}},{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1051\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Others\"},\"renderers\":[{\"id\":\"p1044\"}],\"index\":3}}]}}],\"background_fill_color\":\"#14191B\",\"border_fill_color\":\"#15191C\"}}}},{\"type\":\"object\",\"name\":\"TabPanel\",\"id\":\"p1120\",\"attributes\":{\"title\":\"Failures\",\"child\":{\"type\":\"object\",\"name\":\"Figure\",\"id\":\"p1057\",\"attributes\":{\"sizing_mode\":\"stretch_width\",\"x_range\":{\"type\":\"object\",\"name\":\"Range1d\",\"id\":\"p1066\",\"attributes\":{\"start\":6.380357480049133,\"end\":14.755448627471925}},\"y_range\":{\"type\":\"object\",\"name\":\"Range1d\",\"id\":\"p1067\",\"attributes\":{\"start\":-2.8237056732177734,\"end\":5.5318111181259155}},\"x_scale\":{\"type\":\"object\",\"name\":\"LinearScale\",\"id\":\"p1068\"},\"y_scale\":{\"type\":\"object\",\"name\":\"LinearScale\",\"id\":\"p1069\"},\"title\":{\"type\":\"object\",\"name\":\"Title\",\"id\":\"p1064\",\"attributes\":{\"text_color\":\"#E0E0E0\",\"text_font\":\"Helvetica\",\"text_font_size\":\"14pt\"}},\"outline_line_color\":\"#E0E0E0\",\"outline_line_alpha\":0.25,\"renderers\":[{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p1096\",\"attributes\":{\"data_source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p1053\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p1054\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p1055\"},\"data\":{\"type\":\"map\",\"entries\":[[\"x\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"EBHpQA==\"},\"shape\":[1],\"dtype\":\"float32\",\"order\":\"little\"}],[\"y\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"8Z+oPw==\"},\"shape\":[1],\"dtype\":\"float32\",\"order\":\"little\"}],[\"topic\",[\"Nitisinone Pharmacokinetics\"]],[\"correctness\",[true]],[\"questions\",[\"What are the reproductive risks associated with nitisinone in animals?\"]],[\"agent_answer\",[\"Based on the provided document, there is information about reproductive risks associated with nitisinone in animals. According to the document, animal reproduction studies have been conducted for nitisinone, and the results are as follows:\\\\n\\\\n* In mice, nitisinone caused incomplete skeletal ossification of fetal bones and decreased pup survival at doses 0.4 times the recommended initial dose, and increased gestational length at doses 4 times the recommended initial dose.\\\\n* In rabbits, nitisinone caused maternal toxicity and incomplete skeletal ossification of fetal bones at doses 1.6 times the recommended initial dose.\\\\n\\\\nThese findings suggest that nitisinone may have reproductive risks in animals, particularly in terms of fetal development and survival. However, it is important to note that these studies were conducted in mice and rabbits, and the results may not directly translate to humans. Therefore, more research is needed to fully understand the reproductive risks associated with nitisinone in animals and humans.\"]],[\"reference_answer\",[\"In animal reproduction studies, nitisinone was shown to cause incomplete skeletal ossification of fetal bones and decreased pup survival at doses 0.4 times the recommended initial dose in mice. In addition, increased gestational length was observed at doses 4 times the recommended initial dose in mice, and maternal toxicity and incomplete skeletal ossification of fetal bones were seen at doses 1.6 times the recommended initial dose in rabbits.\"]],[\"id\",[19]],[\"content\",[\"Data\\\\n\\\\nAnimal Data\\\\n\\\\nReproduction studies have been performed in mice at oral doses of about 0.4, 4 and 20 times the recommended initial dose (1 mg/kg/day) and in rabbits at oral doses of about 1.6, 4 and 8 times the recommended initial dose based on the body surface area. In mice, nitisinone has been shown to cause incomplete skeletal ossification of fetal bones at 0.4, 4 and 20 times the recommended initial dose, increased gestational length at 4 and 20 times the recommended initial dose, and de...\"]],[\"color\",[\"#0a980a\"]]]}}},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p1097\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p1098\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1093\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.7},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.7}}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1094\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.1},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.1},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.1}}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1095\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}}}},{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p1110\",\"attributes\":{\"data_source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p1101\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p1102\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p1103\"},\"data\":{\"type\":\"map\",\"entries\":[[\"x\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"m7omQdYJF0FcnxNBl2QEQTQUBUHl3h5Bq/c6QXkdEEG5KQxBW4QSQacWGkGPJyBBFxUpQTb+HEEn+SdBDzz/QEwJ60CWSfFA8UrUQBAR6UCDhgBBFdUiQYa3GEFGfh9BTWYLQa/LMEEAXDtBt48yQbMqHEG+uwtB43QRQcAM8EBZcwJBwvjgQHaeLEE/ezVBgk0vQQnoJUFGvRRBTgkMQcM7IEEzjgRBgK0OQZy6GkEUKhNB9+YOQQ==\"},\"shape\":[46],\"dtype\":\"float32\",\"order\":\"little\"}],[\"y\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"EVckQGNbzj+732q/18+vv0Pj477qBLY/DtOKP0jSpr7kKfc/yQaQPoG9ML+pgsW+az4xPu0ut7+LTpO/TaQBPdB5Jr/pI94/QTKvP/GfqD/aQaE/YsV9P3EiOj44ZhxAE+4yQFjAsj9/TJc+SGg5PykkUz937KQ/rppoP9qhUT4U/tk+wFxAP9EG7j7Pg5i+KZMtv+nb+T8few9A/3ahv12iTUDuRVpA4I9JQPdoZ0Bx62hAiHSEQA==\"},\"shape\":[46],\"dtype\":\"float32\",\"order\":\"little\"}]]}}},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p1111\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p1112\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1107\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"value\",\"value\":\"grey\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"fill_color\":{\"type\":\"value\",\"value\":\"grey\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_color\":{\"type\":\"value\",\"value\":\"grey\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1108\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"value\",\"value\":\"grey\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.1},\"fill_color\":{\"type\":\"value\",\"value\":\"grey\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.1},\"hatch_color\":{\"type\":\"value\",\"value\":\"grey\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.1}}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1109\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"value\",\"value\":\"grey\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"fill_color\":{\"type\":\"value\",\"value\":\"grey\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_color\":{\"type\":\"value\",\"value\":\"grey\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}}}}],\"toolbar\":{\"type\":\"object\",\"name\":\"Toolbar\",\"id\":\"p1065\",\"attributes\":{\"logo\":\"grey\",\"tools\":[{\"type\":\"object\",\"name\":\"PanTool\",\"id\":\"p1080\"},{\"type\":\"object\",\"name\":\"WheelZoomTool\",\"id\":\"p1081\",\"attributes\":{\"renderers\":\"auto\"}},{\"type\":\"object\",\"name\":\"BoxZoomTool\",\"id\":\"p1082\",\"attributes\":{\"overlay\":{\"type\":\"object\",\"name\":\"BoxAnnotation\",\"id\":\"p1083\",\"attributes\":{\"syncable\":false,\"level\":\"overlay\",\"visible\":false,\"left\":{\"type\":\"number\",\"value\":\"nan\"},\"right\":{\"type\":\"number\",\"value\":\"nan\"},\"top\":{\"type\":\"number\",\"value\":\"nan\"},\"bottom\":{\"type\":\"number\",\"value\":\"nan\"},\"left_units\":\"canvas\",\"right_units\":\"canvas\",\"top_units\":\"canvas\",\"bottom_units\":\"canvas\",\"line_color\":\"black\",\"line_alpha\":1.0,\"line_width\":2,\"line_dash\":[4,4],\"fill_color\":\"lightgrey\",\"fill_alpha\":0.5}}}},{\"type\":\"object\",\"name\":\"ResetTool\",\"id\":\"p1088\"},{\"type\":\"object\",\"name\":\"SaveTool\",\"id\":\"p1089\"},{\"type\":\"object\",\"name\":\"HoverTool\",\"id\":\"p1056\",\"attributes\":{\"renderers\":[{\"id\":\"p1096\"}],\"tooltips\":\"\\\\n    &lt;div style=\\\\\"width:400px;\\\\\"&gt;\\\\n    &lt;b&gt;Document id:&lt;/b&gt; @id &lt;br&gt;\\\\n    &lt;b&gt;Topic:&lt;/b&gt; @topic &lt;br&gt;\\\\n    &lt;b&gt;Question:&lt;/b&gt; @questions &lt;br&gt;\\\\n    &lt;b&gt;agent Answer:&lt;/b&gt; @agent_answer &lt;br&gt;\\\\n    &lt;b&gt;Reference Answer:&lt;/b&gt; @reference_answer &lt;br&gt;\\\\n    &lt;b&gt;Correctness:&lt;/b&gt; @correctness &lt;br&gt;\\\\n    &lt;b&gt;Content:&lt;/b&gt; @content\\\\n    &lt;/div&gt;\\\\n    \"}}]}},\"left\":[{\"type\":\"object\",\"name\":\"LinearAxis\",\"id\":\"p1075\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"BasicTicker\",\"id\":\"p1076\",\"attributes\":{\"mantissas\":[1,2,5]}},\"formatter\":{\"type\":\"object\",\"name\":\"BasicTickFormatter\",\"id\":\"p1077\"},\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p1078\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"below\":[{\"type\":\"object\",\"name\":\"LinearAxis\",\"id\":\"p1070\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"BasicTicker\",\"id\":\"p1071\",\"attributes\":{\"mantissas\":[1,2,5]}},\"formatter\":{\"type\":\"object\",\"name\":\"BasicTickFormatter\",\"id\":\"p1072\"},\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p1073\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"center\":[{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p1074\",\"attributes\":{\"axis\":{\"id\":\"p1070\"},\"grid_line_color\":\"white\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p1079\",\"attributes\":{\"dimension\":1,\"axis\":{\"id\":\"p1075\"},\"grid_line_color\":\"white\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Legend\",\"id\":\"p1099\",\"attributes\":{\"title\":\"Question Correctness\",\"title_text_color\":\"#B1B1B1\",\"title_text_font_style\":\"bold\",\"border_line_alpha\":0,\"background_fill_color\":\"#111516\",\"background_fill_alpha\":0.5,\"label_text_color\":\"#E0E0E0\",\"label_text_font\":\"Helvetica\",\"label_text_font_size\":\"1.025em\",\"label_standoff\":8,\"glyph_width\":15,\"spacing\":8,\"items\":[{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1100\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"True\"},\"renderers\":[{\"id\":\"p1096\"}],\"index\":0}}]}},{\"type\":\"object\",\"name\":\"LabelSet\",\"id\":\"p1116\",\"attributes\":{\"level\":\"glyph\",\"source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p1113\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p1114\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p1115\"},\"data\":{\"type\":\"map\",\"entries\":[[\"x\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"7mEyQeIRDkFpIBJB\"},\"shape\":[3],\"dtype\":\"float32\",\"order\":\"little\"}],[\"y\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"TGNrPtvlTT9xdFNA\"},\"shape\":[3],\"dtype\":\"float32\",\"order\":\"little\"}],[\"topic\",[\"Nitisinone Treatment for HT-1\",\"Nitisinone Pharmacokinetics\",\"Nitisinone Capsules\"]]]}}},\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"text\":{\"type\":\"field\",\"field\":\"topic\"},\"text_color\":{\"type\":\"value\",\"value\":\"#B1B1B1\"},\"text_font_size\":{\"type\":\"value\",\"value\":\"12pt\"},\"text_font_style\":{\"type\":\"value\",\"value\":\"bold\"},\"text_align\":{\"type\":\"value\",\"value\":\"center\"}}}],\"background_fill_color\":\"#14191B\",\"border_fill_color\":\"#15191C\"}}}}],\"tabs_location\":\"below\"}}]}}';\n",
       "        const render_items = [{\"docid\":\"76e4be16-ba0e-4137-b0be-f2985b04dc0d\",\"roots\":{\"p1121\":\"f610fa97-d3d0-423a-b404-810376c1a29e\"},\"root_ids\":[\"p1121\"]}];\n",
       "        root.Bokeh.embed.embed_items(docs_json, render_items);\n",
       "        }\n",
       "        if (root.Bokeh !== undefined) {\n",
       "          embed_document(root);\n",
       "        } else {\n",
       "          let attempts = 0;\n",
       "          const timer = setInterval(function(root) {\n",
       "            if (root.Bokeh !== undefined) {\n",
       "              clearInterval(timer);\n",
       "              embed_document(root);\n",
       "            } else {\n",
       "              attempts++;\n",
       "              if (attempts > 100) {\n",
       "                clearInterval(timer);\n",
       "                console.log(\"Bokeh: ERROR: Unable to run BokehJS code because BokehJS library is missing\");\n",
       "              }\n",
       "            }\n",
       "          }, 10, root)\n",
       "        }\n",
       "      })(window);\n",
       "    });\n",
       "  };\n",
       "  if (document.readyState != \"loading\") fn();\n",
       "  else document.addEventListener(\"DOMContentLoaded\", fn);\n",
       "})();\n",
       "    </script>\n",
       "\n",
       "                <div id=\"f610fa97-d3d0-423a-b404-810376c1a29e\" data-root-id=\"p1121\" style=\"display: contents;\"></div>\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"section-card\">\n",
       "\n",
       "                <div class=\"section-title\">SELECTED METRICS</div>\n",
       "\n",
       "                \n",
       "\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        \n",
       "    </div>\n",
       "</div>\n",
       "\n",
       "\n",
       "\n",
       "<script type=\"text/javascript\">\n",
       "    function opentab(evt, name) {\n",
       "    // Declare all variables\n",
       "    let i, tabcontent, tablinks;\n",
       "\n",
       "    // Get all elements with class=\"tabcontent\" and hide them\n",
       "    tabcontent = document.getElementsByClassName(\"tabcontent\");\n",
       "    for (i = 0; i < tabcontent.length; i++) {\n",
       "        tabcontent[i].style.display = \"none\";\n",
       "    }\n",
       "\n",
       "    // Get all elements with class=\"tablinks\" and remove the class \"active\"\n",
       "    tablinks = document.getElementsByClassName(\"tablinks\");\n",
       "    for (i = 0; i < tablinks.length; i++) {\n",
       "        tablinks[i].className = tablinks[i].className.replace(\" active\", \"\");\n",
       "    }\n",
       "\n",
       "    // Show the current tab, and add an \"active\" class to the button that opened the tab\n",
       "    document.getElementById(name).style.display = \"block\";\n",
       "    evt.currentTarget.className += \" active\";\n",
       "}\n",
       "</script>\n"
      ],
      "text/plain": [
       "<giskard.rag.report.RAGReport at 0x20e963df400>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "display(report)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [],
   "source": [
    "report.to_html(\"report.html\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>correctness</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>question_type</th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>simple</th>\n",
       "      <td>1.0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "               correctness\n",
       "question_type             \n",
       "simple                 1.0"
      ]
     },
     "execution_count": 19,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "report.correctness_by_question_type()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>question</th>\n",
       "      <th>reference_answer</th>\n",
       "      <th>reference_context</th>\n",
       "      <th>conversation_history</th>\n",
       "      <th>metadata</th>\n",
       "      <th>agent_answer</th>\n",
       "      <th>correctness</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>id</th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "Empty DataFrame\n",
       "Columns: [question, reference_answer, reference_context, conversation_history, metadata, agent_answer, correctness]\n",
       "Index: []"
      ]
     },
     "execution_count": 20,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "report.get_failures()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Failures saved to giskard_failures.xlsx\n"
     ]
    }
   ],
   "source": [
    "import pandas as pd\n",
    "\n",
    "# Assuming `report.get_failures()` returns a list of dicts or objects\n",
    "failures = report.get_failures()\n",
    "\n",
    "# If it's already a list of dictionaries, this will work:\n",
    "df_failures = pd.DataFrame(failures)\n",
    "\n",
    "# Save to Excel\n",
    "df_failures.to_excel(\"giskard_failures.xlsx\", index=False)\n",
    "print(\"Failures saved to giskard_failures.xlsx\")\n"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "venv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.10"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
